Skip to main content
Top
Published in: Journal of Neurology 10/2023

05-08-2023 | Optic Neuritis | Neurological Update

An update on optic neuritis

Authors: Jessica A. Kraker, John J. Chen

Published in: Journal of Neurology | Issue 10/2023

Login to get access

Abstract

Optic neuritis (ON) is the most common cause of subacute optic neuropathy in young adults. Although most cases of optic neuritis (ON) are classified as typical, meaning idiopathic or associated with multiple sclerosis, there is a growing understanding of atypical forms of optic neuritis such as antibody mediated aquaporin-4 (AQP4)-IgG neuromyelitis optica spectrum disorder (NMOSD) and the recently described entity, myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD). Differentiating typical ON from atypical ON is important because they have different prognoses and treatments. Findings of atypical ON, including severe vision loss with poor recovery with steroids or steroid dependence, prominent optic disc edema, bilateral vision loss, and childhood or late adult onset, should prompt serologic testing for AQP4-IgG and MOG-IgG. Although the traditional division of typical and atypical ON can be helpful, it should be noted that there can be severe presentations of otherwise typical ON and mild presentations of atypical ON that blur these traditional lines. Rare causes of autoimmune optic neuropathies, such as glial fibrillary acidic protein (GFAP) and collapsin response-mediator protein 5 (CRMP5) autoimmunity also should be considered in patients with bilateral painless optic neuropathy associated with optic disc edema, especially if there are other accompanying suggestive neurologic symptoms/signs. Typical ON usually recovers well without treatment, though recovery may be expedited by steroids. Atypical ON is usually treated with intravenous steroids, and some forms, such as NMOSD, often require plasma exchange for acute attacks and long-term immunosuppressive therapy to prevent relapses. Since treatment is tailored to the cause of the ON, elucidating the etiology of the ON is of the utmost importance.
Literature
2.
go back to reference Jin YP, de Pedro-Cuesta J, Soderstrom M, Link H (1999) Incidence of optic neuritis in Stockholm, Sweden, 1990–1995: II. Time and space patterns. Arch Neurol 56:975–980PubMedCrossRef Jin YP, de Pedro-Cuesta J, Soderstrom M, Link H (1999) Incidence of optic neuritis in Stockholm, Sweden, 1990–1995: II. Time and space patterns. Arch Neurol 56:975–980PubMedCrossRef
3.
go back to reference Rodriguez M, Siva A, Cross SA, O’Brien PC, Kurland LT (1995) Optic neuritis: a population-based study in Olmsted County, Minnesota. Neurology 45:244–250PubMedCrossRef Rodriguez M, Siva A, Cross SA, O’Brien PC, Kurland LT (1995) Optic neuritis: a population-based study in Olmsted County, Minnesota. Neurology 45:244–250PubMedCrossRef
4.
go back to reference Soelberg K, Jarius S, Skejoe H, Engberg H, Mehlsen JJ, Nilsson AC, Madsen JS, Reindl M, Wildemann B, Grauslund J, Kyvik KO, Smith TJ, Lillevang ST, Paul F, Weinshenker BG, Asgari N (2017) A population-based prospective study of optic neuritis. Mult Scler 23:1893–1901PubMedCrossRef Soelberg K, Jarius S, Skejoe H, Engberg H, Mehlsen JJ, Nilsson AC, Madsen JS, Reindl M, Wildemann B, Grauslund J, Kyvik KO, Smith TJ, Lillevang ST, Paul F, Weinshenker BG, Asgari N (2017) A population-based prospective study of optic neuritis. Mult Scler 23:1893–1901PubMedCrossRef
5.
go back to reference Hassan MB, Stern C, Flanagan EP, Pittock SJ, Kunchok A, Foster RC, Jitprapaikulsan J, Hodge DO, Bhatti MT, Chen JJ (2020) Population-based incidence of optic neuritis in the era of aquaporin-4 and myelin oligodendrocyte glycoprotein antibodies. Am J Ophthalmol 220:110–114PubMedCrossRefPubMedCentral Hassan MB, Stern C, Flanagan EP, Pittock SJ, Kunchok A, Foster RC, Jitprapaikulsan J, Hodge DO, Bhatti MT, Chen JJ (2020) Population-based incidence of optic neuritis in the era of aquaporin-4 and myelin oligodendrocyte glycoprotein antibodies. Am J Ophthalmol 220:110–114PubMedCrossRefPubMedCentral
6.
go back to reference Optic Neuritis Study Group (2008) Multiple sclerosis risk after optic neuritis: final optic neuritis treatment trial follow-up. Arch Neurol 65(6):727–732 Optic Neuritis Study Group (2008) Multiple sclerosis risk after optic neuritis: final optic neuritis treatment trial follow-up. Arch Neurol 65(6):727–732
7.
go back to reference Chen JJ, Tobin WO, Majed M, Jitprapaikulsan J, Fryer JP, Leavitt JA, Flanagan EP, McKeon A, Pittock SJ (2018) Prevalence of myelin oligodendrocyte glycoprotein and aquaporin-4-IgG in patients in the optic neuritis treatment trial. JAMA Ophthalmol 136(4):419–422PubMedCrossRefPubMedCentral Chen JJ, Tobin WO, Majed M, Jitprapaikulsan J, Fryer JP, Leavitt JA, Flanagan EP, McKeon A, Pittock SJ (2018) Prevalence of myelin oligodendrocyte glycoprotein and aquaporin-4-IgG in patients in the optic neuritis treatment trial. JAMA Ophthalmol 136(4):419–422PubMedCrossRefPubMedCentral
8.
go back to reference Optic Neuritis Study Group (2008) Visual function 15 years after optic neuritis: a final follow-up report from the optic neuritis treatment trial. Ophthalmology 115(6):1079-1082.e5CrossRef Optic Neuritis Study Group (2008) Visual function 15 years after optic neuritis: a final follow-up report from the optic neuritis treatment trial. Ophthalmology 115(6):1079-1082.e5CrossRef
9.
go back to reference Nilsson P, Larsson EM, Maly-Sundgren P, Perfekt R, Sandberg-Wollheim M (2005) Predicting the outcome of optic neuritis: evaluation of risk factors after 30 years of follow-up. J Neurol 252(4):396–402PubMedCrossRef Nilsson P, Larsson EM, Maly-Sundgren P, Perfekt R, Sandberg-Wollheim M (2005) Predicting the outcome of optic neuritis: evaluation of risk factors after 30 years of follow-up. J Neurol 252(4):396–402PubMedCrossRef
10.
go back to reference Beck RW, Cleary PA, Anderson MM Jr, Keltner JL, Shults WT, Kaufman DI, Buckley EG, Corbett JJ, Kupersmith MJ, Miller NR et al (1992) A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group. N Engl J Med 326(9):581–588PubMedCrossRef Beck RW, Cleary PA, Anderson MM Jr, Keltner JL, Shults WT, Kaufman DI, Buckley EG, Corbett JJ, Kupersmith MJ, Miller NR et al (1992) A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group. N Engl J Med 326(9):581–588PubMedCrossRef
11.
go back to reference Keltner JL, Johnson CA, Spurr JO, Beck RW (1993) Baseline visual field profile of optic neuritis. The experience of the optic neuritis treatment trial. Optic Neuritis Study Group. Arch Ophthalmol 111:231–234PubMedCrossRef Keltner JL, Johnson CA, Spurr JO, Beck RW (1993) Baseline visual field profile of optic neuritis. The experience of the optic neuritis treatment trial. Optic Neuritis Study Group. Arch Ophthalmol 111:231–234PubMedCrossRef
12.
go back to reference Keltner JL, Johnson CA, Spurr JO, Beck RW (1999) Comparison of central and peripheral visual field properties in the optic neuritis treatment trial. Am J Ophthalmol 128:543–553PubMedCrossRef Keltner JL, Johnson CA, Spurr JO, Beck RW (1999) Comparison of central and peripheral visual field properties in the optic neuritis treatment trial. Am J Ophthalmol 128:543–553PubMedCrossRef
13.
go back to reference Hickman SJ, Petzold A (2021) Update on optic neuritis: an international view. Neuro-Ophthalmology 30:1–8 Hickman SJ, Petzold A (2021) Update on optic neuritis: an international view. Neuro-Ophthalmology 30:1–8
15.
go back to reference Brodsky M, Nazarian S, Orengo-Nania S et al (2008) Multiple sclerosis risk after optic neuritis - Final optic neuritis treatment trial follow-up. Arch Neurol 65:727–732 Brodsky M, Nazarian S, Orengo-Nania S et al (2008) Multiple sclerosis risk after optic neuritis - Final optic neuritis treatment trial follow-up. Arch Neurol 65:727–732
16.
go back to reference McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, McFarland HF, Paty DW, Polman CH, Reingold SC, Sandberg-Wollheim M, Sibley W, Thompson A, van den Noort S, Weinshenker BY, Wolinsky JS (2001) Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 50(1):121–127PubMedCrossRef McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, McFarland HF, Paty DW, Polman CH, Reingold SC, Sandberg-Wollheim M, Sibley W, Thompson A, van den Noort S, Weinshenker BY, Wolinsky JS (2001) Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 50(1):121–127PubMedCrossRef
17.
go back to reference Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, Correale J, Fazekas F, Filippi M, Freedman MS, Fujihara K, Galetta SL, Hartung HP, Kappos L, Lublin FD, Marrie RA, Miller AE, Miller DH, Montalban X, Mowry EM, Sorensen PS, Tintoré M, Traboulsee AL, Trojano M, Uitdehaag BMJ, Vukusic S, Waubant E, Weinshenker BG, Reingold SC, Cohen JA (2018) Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 17(2):162–173PubMedCrossRef Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, Correale J, Fazekas F, Filippi M, Freedman MS, Fujihara K, Galetta SL, Hartung HP, Kappos L, Lublin FD, Marrie RA, Miller AE, Miller DH, Montalban X, Mowry EM, Sorensen PS, Tintoré M, Traboulsee AL, Trojano M, Uitdehaag BMJ, Vukusic S, Waubant E, Weinshenker BG, Reingold SC, Cohen JA (2018) Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 17(2):162–173PubMedCrossRef
18.
go back to reference Brownlee WJ, Miszkiel KA, Tur C, Barkhof F, Miller DH, Ciccarelli O (2018) Inclusion of optic nerve involvement in dissemination in space criteria for multiple sclerosis. Neurology 91:e1130–e1134PubMedCrossRefPubMedCentral Brownlee WJ, Miszkiel KA, Tur C, Barkhof F, Miller DH, Ciccarelli O (2018) Inclusion of optic nerve involvement in dissemination in space criteria for multiple sclerosis. Neurology 91:e1130–e1134PubMedCrossRefPubMedCentral
19.
go back to reference Vidal-Jordana A, Rovira A, Arrambide G, Otero-Romero S, Río J, Comabella M, Nos C, Castilló J, Galan I, Cabello S, Moncho D, Rahnama K, Thonon V, Rodríguez-Acevedo B, Zabalza A, Midaglia L, Auger C, Sastre-Garriga J, Montalban X, Tintoré M (2021) Optic nerve topography in multiple sclerosis diagnosis: the utility of visual evoked potentials. Neurology 96(4):e482–e490PubMedCrossRefPubMedCentral Vidal-Jordana A, Rovira A, Arrambide G, Otero-Romero S, Río J, Comabella M, Nos C, Castilló J, Galan I, Cabello S, Moncho D, Rahnama K, Thonon V, Rodríguez-Acevedo B, Zabalza A, Midaglia L, Auger C, Sastre-Garriga J, Montalban X, Tintoré M (2021) Optic nerve topography in multiple sclerosis diagnosis: the utility of visual evoked potentials. Neurology 96(4):e482–e490PubMedCrossRefPubMedCentral
20.
go back to reference Francis DA, Compston DA, Batchelor JR, McDonald WI (1987) A reassessment of the risk of multiple sclerosis developing in patients with optic neuritis after extended follow-up. J Neurol Neurosurg Psychiatry 50(6):758–765PubMedCrossRefPubMedCentral Francis DA, Compston DA, Batchelor JR, McDonald WI (1987) A reassessment of the risk of multiple sclerosis developing in patients with optic neuritis after extended follow-up. J Neurol Neurosurg Psychiatry 50(6):758–765PubMedCrossRefPubMedCentral
21.
go back to reference Sandberg-Wollheim M (1975) Optic neuritis: studies on the cerebrospinal fluid in relation to clinical course in 61 patients. Acta Neurol Scand 52(3):167–178PubMedCrossRef Sandberg-Wollheim M (1975) Optic neuritis: studies on the cerebrospinal fluid in relation to clinical course in 61 patients. Acta Neurol Scand 52(3):167–178PubMedCrossRef
22.
go back to reference Nolan-Kenney RC, Liu M, Akhand O, Calabresi PA, Paul F, Petzold A, Balk L, Brandt AU, Martínez-Lapiscina EH, Saidha S, Villoslada P, Al-Hassan AA, Behbehani R, Frohman EM, Frohman T, Havla J, Hemmer B, Jiang H, Knier B, Korn T, Leocani L, Papadopoulou A, Pisa M, Zimmermann H, Galetta SL, Balcer LJ, International Multiple Sclerosis Visual System Consortium (2019) Optimal intereye difference thresholds by optical coherence tomography in multiple sclerosis: an international study. Ann Neurol 85(5):618–629PubMedCrossRef Nolan-Kenney RC, Liu M, Akhand O, Calabresi PA, Paul F, Petzold A, Balk L, Brandt AU, Martínez-Lapiscina EH, Saidha S, Villoslada P, Al-Hassan AA, Behbehani R, Frohman EM, Frohman T, Havla J, Hemmer B, Jiang H, Knier B, Korn T, Leocani L, Papadopoulou A, Pisa M, Zimmermann H, Galetta SL, Balcer LJ, International Multiple Sclerosis Visual System Consortium (2019) Optimal intereye difference thresholds by optical coherence tomography in multiple sclerosis: an international study. Ann Neurol 85(5):618–629PubMedCrossRef
23.
go back to reference Petzold A, Chua SYL, Khawaja AP, Keane PA, Khaw PT, Reisman C, Dhillon B, Strouthidis NG, Foster PJ, Patel PJ, UK Biobank Eye and Vision Consortium (2021) Retinal asymmetry in multiple sclerosis. Brain 144(1):224–235PubMedCrossRef Petzold A, Chua SYL, Khawaja AP, Keane PA, Khaw PT, Reisman C, Dhillon B, Strouthidis NG, Foster PJ, Patel PJ, UK Biobank Eye and Vision Consortium (2021) Retinal asymmetry in multiple sclerosis. Brain 144(1):224–235PubMedCrossRef
24.
go back to reference Beck RW, Gal RL, Bhatti MT, Brodsky MC, Buckley EG, Chrousos GA, Corbett J, Eggenberger E, Goodwin JA, Katz B, Kaufman DI, Keltner JL, Kupersmith MJ, Miller NR, Moke PS, Nazarian S, Orengo-Nania S, Savino PJ, Shults WT, Smith CH, Trobe JD, Wall M, Xing D, Optic Neuritis Study Group (2004) Visual function more than 10 years after optic neuritis: experience of the optic neuritis treatment trial. Am J Ophthalmol 137(1):77–83PubMedCrossRef Beck RW, Gal RL, Bhatti MT, Brodsky MC, Buckley EG, Chrousos GA, Corbett J, Eggenberger E, Goodwin JA, Katz B, Kaufman DI, Keltner JL, Kupersmith MJ, Miller NR, Moke PS, Nazarian S, Orengo-Nania S, Savino PJ, Shults WT, Smith CH, Trobe JD, Wall M, Xing D, Optic Neuritis Study Group (2004) Visual function more than 10 years after optic neuritis: experience of the optic neuritis treatment trial. Am J Ophthalmol 137(1):77–83PubMedCrossRef
25.
go back to reference Morrow SA, Fraser JA, Day C, Bowman D, Rosehart H, Kremenchutzky M, Nicolle M (2018) Effect of Treating acute optic neuritis with bioequivalent oral vs intravenous corticosteroids: a randomized clinical trial. JAMA Neurol 75(6):690–696PubMedCrossRefPubMedCentral Morrow SA, Fraser JA, Day C, Bowman D, Rosehart H, Kremenchutzky M, Nicolle M (2018) Effect of Treating acute optic neuritis with bioequivalent oral vs intravenous corticosteroids: a randomized clinical trial. JAMA Neurol 75(6):690–696PubMedCrossRefPubMedCentral
26.
go back to reference Chen JJ, Pittock SJ, Flanagan EP, Lennon VA, Bhatti MT (2020) Optic neuritis in the era of biomarkers. Surv Ophthalmol 65(1):12–17PubMedCrossRef Chen JJ, Pittock SJ, Flanagan EP, Lennon VA, Bhatti MT (2020) Optic neuritis in the era of biomarkers. Surv Ophthalmol 65(1):12–17PubMedCrossRef
27.
go back to reference Jarius S, Paul F, Weinshenker BG, Levy M, Kim HJ, Wildemann B (2020) Neuromyelitis optica. Nat Rev Dis Primers 6(1):85PubMedCrossRef Jarius S, Paul F, Weinshenker BG, Levy M, Kim HJ, Wildemann B (2020) Neuromyelitis optica. Nat Rev Dis Primers 6(1):85PubMedCrossRef
28.
go back to reference Kleiter I, Gahlen A, Borisow N, Fischer K, Wernecke KD, Wegner B, Hellwig K, Pache F, Ruprecht K, Havla J, Krumbholz M, Kümpfel T, Aktas O, Hartung HP, Ringelstein M, Geis C, Kleinschnitz C, Berthele A, Hemmer B, Angstwurm K, Stellmann JP, Schuster S, Stangel M, Lauda F, Tumani H, Mayer C, Zeltner L, Ziemann U, Linker R, Schwab M, Marziniak M, Then Bergh F, Hofstadt-van Oy U, Neuhaus O, Winkelmann A, Marouf W, Faiss J, Wildemann B, Paul F, Jarius S, Trebst C, Neuromyelitis Optica Study Group (2016) Neuromyelitis optica: Evaluation of 871 attacks and 1,153 treatment courses. Ann Neurol 79(2):206–216PubMedCrossRef Kleiter I, Gahlen A, Borisow N, Fischer K, Wernecke KD, Wegner B, Hellwig K, Pache F, Ruprecht K, Havla J, Krumbholz M, Kümpfel T, Aktas O, Hartung HP, Ringelstein M, Geis C, Kleinschnitz C, Berthele A, Hemmer B, Angstwurm K, Stellmann JP, Schuster S, Stangel M, Lauda F, Tumani H, Mayer C, Zeltner L, Ziemann U, Linker R, Schwab M, Marziniak M, Then Bergh F, Hofstadt-van Oy U, Neuhaus O, Winkelmann A, Marouf W, Faiss J, Wildemann B, Paul F, Jarius S, Trebst C, Neuromyelitis Optica Study Group (2016) Neuromyelitis optica: Evaluation of 871 attacks and 1,153 treatment courses. Ann Neurol 79(2):206–216PubMedCrossRef
29.
go back to reference Min JH, Kim BJ, Lee KH (2012) Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder. Mult Scler 18:113–115PubMedCrossRef Min JH, Kim BJ, Lee KH (2012) Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder. Mult Scler 18:113–115PubMedCrossRef
30.
go back to reference Kleiter I, Hellwig K, Berthele A, Kümpfel T, Linker RA, Hartung HP, Paul F, Aktas O, Neuromyelitis Optica Study Group (2012) Failure of natalizumab to prevent relapses in neuromyelitis optica. Arch Neurol 69(2):239–245PubMedCrossRef Kleiter I, Hellwig K, Berthele A, Kümpfel T, Linker RA, Hartung HP, Paul F, Aktas O, Neuromyelitis Optica Study Group (2012) Failure of natalizumab to prevent relapses in neuromyelitis optica. Arch Neurol 69(2):239–245PubMedCrossRef
31.
go back to reference Kim SH, Kim W, Li XF, Jung IJ, Kim HJ (2012) Does interferon beta treatment exacerbate neuromyelitis optica spectrum disorder? Mult Scler 18:1480–1483PubMedCrossRef Kim SH, Kim W, Li XF, Jung IJ, Kim HJ (2012) Does interferon beta treatment exacerbate neuromyelitis optica spectrum disorder? Mult Scler 18:1480–1483PubMedCrossRef
32.
go back to reference Chen JJ, Flanagan EP, Jitprapaikulsan J, López-Chiriboga ASS, Fryer JP, Leavitt JA, Weinshenker BG, McKeon A, Tillema JM, Lennon VA, Tobin WO, Keegan BM, Lucchinetti CF, Kantarci OH, McClelland CM, Lee MS, Bennett JL, Pelak VS, Chen Y, VanStavern G, Adesina OO, Eggenberger ER, Acierno MD, Wingerchuk DM, Brazis PW, Sagen J, Pittock SJ (2018) Myelin oligodendrocyte glycoprotein antibody-positive optic neuritis: clinical characteristics, radiologic clues, and outcome. Am J Ophthalmol 195:8–15PubMedCrossRefPubMedCentral Chen JJ, Flanagan EP, Jitprapaikulsan J, López-Chiriboga ASS, Fryer JP, Leavitt JA, Weinshenker BG, McKeon A, Tillema JM, Lennon VA, Tobin WO, Keegan BM, Lucchinetti CF, Kantarci OH, McClelland CM, Lee MS, Bennett JL, Pelak VS, Chen Y, VanStavern G, Adesina OO, Eggenberger ER, Acierno MD, Wingerchuk DM, Brazis PW, Sagen J, Pittock SJ (2018) Myelin oligodendrocyte glycoprotein antibody-positive optic neuritis: clinical characteristics, radiologic clues, and outcome. Am J Ophthalmol 195:8–15PubMedCrossRefPubMedCentral
33.
go back to reference Ramanathan S, Mohammad S, Tantsis E, Nguyen TK, Merheb V, Fung VSC, White OB, Broadley S, Lechner-Scott J, Vucic S, Henderson APD, Barnett MH, Reddel SW, Brilot F, Dale RC, Australasian and New Zealand MOG Study Group (2018) Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination. J Neurol Neurosurg Psychiatry 89(2):127–137PubMedCrossRef Ramanathan S, Mohammad S, Tantsis E, Nguyen TK, Merheb V, Fung VSC, White OB, Broadley S, Lechner-Scott J, Vucic S, Henderson APD, Barnett MH, Reddel SW, Brilot F, Dale RC, Australasian and New Zealand MOG Study Group (2018) Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination. J Neurol Neurosurg Psychiatry 89(2):127–137PubMedCrossRef
34.
go back to reference Chen JJ, Flanagan EP, Bhatti MT, Jitprapaikulsan J, Dubey D, Lopez Chiriboga ASS, Fryer JP, Weinshenker BG, McKeon A, Tillema JM, Lennon VA, Lucchinetti CF, Kunchok A, McClelland CM, Lee MS, Bennett JL, Pelak VS, Van Stavern G, Adesina OO, Eggenberger ER, Acierno MD, Wingerchuk DM, Lam BL, Moss H, Beres S, Gilbert AL, Shah V, Armstrong G, Heidary G, Cestari DM, Stiebel-Kalish H, Pittock SJ (2020) Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder. Neurology 95(2):e111–e120PubMedCrossRefPubMedCentral Chen JJ, Flanagan EP, Bhatti MT, Jitprapaikulsan J, Dubey D, Lopez Chiriboga ASS, Fryer JP, Weinshenker BG, McKeon A, Tillema JM, Lennon VA, Lucchinetti CF, Kunchok A, McClelland CM, Lee MS, Bennett JL, Pelak VS, Van Stavern G, Adesina OO, Eggenberger ER, Acierno MD, Wingerchuk DM, Lam BL, Moss H, Beres S, Gilbert AL, Shah V, Armstrong G, Heidary G, Cestari DM, Stiebel-Kalish H, Pittock SJ (2020) Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder. Neurology 95(2):e111–e120PubMedCrossRefPubMedCentral
35.
go back to reference Cobo-Calvo A, Ruiz A, Rollot F, Arrambide G, Deschamps R, Maillart E, Papeix C, Audoin B, Lépine AF, Maurey H, Zephir H, Biotti D, Ciron J, Durand-Dubief F, Collongues N, Ayrignac X, Labauge P, Meyer P, Thouvenot E, Bourre B, Montcuquet A, Cohen M, Horello P, Tintoré M, De Seze J, Vukusic S, Deiva K, Marignier R, NOMADMUS, KIDBIOSEP, and OFSEP Study Groups (2021) Clinical features and risk of relapse in children and adults with myelin oligodendrocyte glycoprotein antibody-associated disease. Ann Neurol 89(1):30–41PubMedCrossRef Cobo-Calvo A, Ruiz A, Rollot F, Arrambide G, Deschamps R, Maillart E, Papeix C, Audoin B, Lépine AF, Maurey H, Zephir H, Biotti D, Ciron J, Durand-Dubief F, Collongues N, Ayrignac X, Labauge P, Meyer P, Thouvenot E, Bourre B, Montcuquet A, Cohen M, Horello P, Tintoré M, De Seze J, Vukusic S, Deiva K, Marignier R, NOMADMUS, KIDBIOSEP, and OFSEP Study Groups (2021) Clinical features and risk of relapse in children and adults with myelin oligodendrocyte glycoprotein antibody-associated disease. Ann Neurol 89(1):30–41PubMedCrossRef
36.
go back to reference Jarius S, Ruprecht K, Kleiter I, Borisow N, Asgari N, Pitarokoili K, Pache F, Stich O, Beume LA, Hummert MW et al (2016) MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflamm 13:280CrossRef Jarius S, Ruprecht K, Kleiter I, Borisow N, Asgari N, Pitarokoili K, Pache F, Stich O, Beume LA, Hummert MW et al (2016) MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflamm 13:280CrossRef
37.
go back to reference Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, de Seze J, Fujihara K, Greenberg B, Jacob A, Jarius S, Lana-Peixoto M, Levy M, Simon JH, Tenembaum S, Traboulsee AL, Waters P, Wellik KE, Weinshenker BG, International Panel for NMO Diagnosis (2015) International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 85(2):177–189PubMedCrossRefPubMedCentral Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, de Seze J, Fujihara K, Greenberg B, Jacob A, Jarius S, Lana-Peixoto M, Levy M, Simon JH, Tenembaum S, Traboulsee AL, Waters P, Wellik KE, Weinshenker BG, International Panel for NMO Diagnosis (2015) International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 85(2):177–189PubMedCrossRefPubMedCentral
38.
go back to reference Flanagan EP, Cabre P, Weinshenker BG, Sauver JS, Jacobson DJ, Majed M, Lennon VA, Lucchinetti CF, McKeon A, Matiello M, Kale N, Wingerchuk DM, Mandrekar J, Sagen JA, Fryer JP, Robinson AB, Pittock SJ (2016) Epidemiology of aquaporin-4 autoimmunity and neuromyelitis optica spectrum. Ann Neurol 79(5):775–783PubMedCrossRefPubMedCentral Flanagan EP, Cabre P, Weinshenker BG, Sauver JS, Jacobson DJ, Majed M, Lennon VA, Lucchinetti CF, McKeon A, Matiello M, Kale N, Wingerchuk DM, Mandrekar J, Sagen JA, Fryer JP, Robinson AB, Pittock SJ (2016) Epidemiology of aquaporin-4 autoimmunity and neuromyelitis optica spectrum. Ann Neurol 79(5):775–783PubMedCrossRefPubMedCentral
39.
go back to reference Ramanathan S, Prelog K, Barnes EH, Tantsis EM, Reddel SW, Henderson AP, Vucic S, Gorman MP, Benson LA, Alper G, Riney CJ, Barnett M, Parratt JD, Hardy TA, Leventer RJ, Merheb V, Nosadini M, Fung VS, Brilot F, Dale RC (2016) Radiological differentiation of optic neuritis with myelin oligodendrocyte glycoprotein antibodies, aquaporin-4 antibodies, and multiple sclerosis. Mult Scler 22(4):470–482PubMedCrossRef Ramanathan S, Prelog K, Barnes EH, Tantsis EM, Reddel SW, Henderson AP, Vucic S, Gorman MP, Benson LA, Alper G, Riney CJ, Barnett M, Parratt JD, Hardy TA, Leventer RJ, Merheb V, Nosadini M, Fung VS, Brilot F, Dale RC (2016) Radiological differentiation of optic neuritis with myelin oligodendrocyte glycoprotein antibodies, aquaporin-4 antibodies, and multiple sclerosis. Mult Scler 22(4):470–482PubMedCrossRef
40.
go back to reference Pandit L, Asgari N, Apiwattanakul M, Palace J, Paul F, Leite MI, Kleiter I, Chitnis T, GJCF International Clinical Consortium & Biorepository for Neuromyelitis Optica (2015) Demographic and clinical features of neuromyelitis optica: a review. Mult Scler 21(7):845–853PubMedCrossRefPubMedCentral Pandit L, Asgari N, Apiwattanakul M, Palace J, Paul F, Leite MI, Kleiter I, Chitnis T, GJCF International Clinical Consortium & Biorepository for Neuromyelitis Optica (2015) Demographic and clinical features of neuromyelitis optica: a review. Mult Scler 21(7):845–853PubMedCrossRefPubMedCentral
41.
go back to reference Liu H, Zhou H, Wang J, Xu Q, Wei S (2019) Antibodies to myelin oligodendrocyte glycoprotein in chronic relapsing inflammatory optic neuropathy. Br J Ophthalmol 103:1423–1428PubMedCrossRef Liu H, Zhou H, Wang J, Xu Q, Wei S (2019) Antibodies to myelin oligodendrocyte glycoprotein in chronic relapsing inflammatory optic neuropathy. Br J Ophthalmol 103:1423–1428PubMedCrossRef
42.
go back to reference Zhou H, Zhao S, Yin D, Chen X, Xu Q, Chen T, Li X, Wang J, Li H, Peng C, Lin D, Wei S (2016) Optic neuritis: a 5-year follow-up study of Chinese patients based on aquaporin-4 antibody status and ages. J Neurol 263(7):1382–1389PubMedCrossRef Zhou H, Zhao S, Yin D, Chen X, Xu Q, Chen T, Li X, Wang J, Li H, Peng C, Lin D, Wei S (2016) Optic neuritis: a 5-year follow-up study of Chinese patients based on aquaporin-4 antibody status and ages. J Neurol 263(7):1382–1389PubMedCrossRef
43.
go back to reference Dutra BG, da Rocha AJ, Nunes RH, Maia ACMJ (2018) Neuromyelitis optica spectrum disorders: Spectrum of MR imaging findings and their differential diagnosis. Radiographics 38(1):16e93CrossRef Dutra BG, da Rocha AJ, Nunes RH, Maia ACMJ (2018) Neuromyelitis optica spectrum disorders: Spectrum of MR imaging findings and their differential diagnosis. Radiographics 38(1):16e93CrossRef
44.
go back to reference Jarius S, Frederikson J, Waters P, Paul F, Akman-Demir G, Marignier R, Franciotta D, Ruprecht K, Kuenz B, Rommer P, Kristoferitsch W, Wildemann B, Vincent A (2010) Frequency and prognostic impact of antibodies to aquaporin-4 in patients with optic neuritis. J Neurol Sci 298(1–2):158–162PubMedCrossRef Jarius S, Frederikson J, Waters P, Paul F, Akman-Demir G, Marignier R, Franciotta D, Ruprecht K, Kuenz B, Rommer P, Kristoferitsch W, Wildemann B, Vincent A (2010) Frequency and prognostic impact of antibodies to aquaporin-4 in patients with optic neuritis. J Neurol Sci 298(1–2):158–162PubMedCrossRef
45.
go back to reference Fernandes DB, Ramos Rde I, Falcochio C, Apóstolos-Pereira S, Callegaro D, Monteiro ML (2012) Comparison of visual acuity and automated perimetry findings in patients with neuromyelitis optica or multiple sclerosis after single or multiple attacks of optic neuritis. J Neuroophthalmol 32(2):102–106PubMedCrossRef Fernandes DB, Ramos Rde I, Falcochio C, Apóstolos-Pereira S, Callegaro D, Monteiro ML (2012) Comparison of visual acuity and automated perimetry findings in patients with neuromyelitis optica or multiple sclerosis after single or multiple attacks of optic neuritis. J Neuroophthalmol 32(2):102–106PubMedCrossRef
46.
go back to reference Jitprapaikulsan J, Chen JJ, Flanagan EP, Tobin WO, Fryer JP, Weinshenker BG, McKeon A, Lennon VA, Leavitt JA, Tillema JM, Lucchinetti C, Keegan BM, Kantarci O, Khanna C, Jenkins SM, Spears GM, Sagan J, Pittock SJ (2018) Aquaporin-4 and myelin oligodendrocyte glycoprotein autoantibody status predict outcome of recurrent optic neuritis. Ophthalmology 125(10):1628–1637PubMedCrossRef Jitprapaikulsan J, Chen JJ, Flanagan EP, Tobin WO, Fryer JP, Weinshenker BG, McKeon A, Lennon VA, Leavitt JA, Tillema JM, Lucchinetti C, Keegan BM, Kantarci O, Khanna C, Jenkins SM, Spears GM, Sagan J, Pittock SJ (2018) Aquaporin-4 and myelin oligodendrocyte glycoprotein autoantibody status predict outcome of recurrent optic neuritis. Ophthalmology 125(10):1628–1637PubMedCrossRef
47.
go back to reference Bennett JL, Costello F, Chen JJ, Petzold A, Biousse V, Newman NJ, Galetta SL (2023) Optic neuritis and autoimmune optic neuropathies: advances in diagnosis and treatment. Lancet Neurol 22(1):89–100PubMedCrossRef Bennett JL, Costello F, Chen JJ, Petzold A, Biousse V, Newman NJ, Galetta SL (2023) Optic neuritis and autoimmune optic neuropathies: advances in diagnosis and treatment. Lancet Neurol 22(1):89–100PubMedCrossRef
48.
go back to reference Sato DK, Callegaro D, Lana-Peixoto MA, Waters PJ, de Haidar Jorge FM, Takahashi T, Nakashima I, Apostolos-Pereira SL, Talim N, Simm RF, Lino AM, Misu T, Leite MI, Aoki M, Fujihara K (2014) Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology 82(6):474–481PubMedCrossRefPubMedCentral Sato DK, Callegaro D, Lana-Peixoto MA, Waters PJ, de Haidar Jorge FM, Takahashi T, Nakashima I, Apostolos-Pereira SL, Talim N, Simm RF, Lino AM, Misu T, Leite MI, Aoki M, Fujihara K (2014) Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology 82(6):474–481PubMedCrossRefPubMedCentral
49.
go back to reference Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K et al (2004) A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 364(9451):2106–2112PubMedCrossRef Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K et al (2004) A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 364(9451):2106–2112PubMedCrossRef
50.
go back to reference Borisow N, Mori M, Kuwabara S, Scheel M, Paul F (2018) Diagnosis and treatment of NMO spectrum disorder and MOG-encephalomyelitis. Front Neurol 23(9):888CrossRef Borisow N, Mori M, Kuwabara S, Scheel M, Paul F (2018) Diagnosis and treatment of NMO spectrum disorder and MOG-encephalomyelitis. Front Neurol 23(9):888CrossRef
51.
go back to reference Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR (2005) IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 202(4):473–477PubMedCrossRefPubMedCentral Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR (2005) IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 202(4):473–477PubMedCrossRefPubMedCentral
52.
go back to reference Prasad S, Chen J (2019) What you need to know about AQP4, MOG, and NMOSD. Semin Neurol 39(6):718–731PubMedCrossRef Prasad S, Chen J (2019) What you need to know about AQP4, MOG, and NMOSD. Semin Neurol 39(6):718–731PubMedCrossRef
53.
54.
go back to reference Furman CS, Gorelick-Feldman DA, Davidson KG et al (2003) Aquaporin-4 square array assembly: opposing actions of M1 and M23 isoforms. Proc Natl Acad Sci USA 100(23):13609–13614PubMedCrossRefPubMedCentral Furman CS, Gorelick-Feldman DA, Davidson KG et al (2003) Aquaporin-4 square array assembly: opposing actions of M1 and M23 isoforms. Proc Natl Acad Sci USA 100(23):13609–13614PubMedCrossRefPubMedCentral
55.
go back to reference Matiello M, Schaefer-Klein J, Sun D, Weinshenker BG (2013) Aquaporin-4 expression and tissue susceptibility to neuromyelitis optica. JAMA Neurol 70(09):1118–1125 (Seminars in Neurology Vol. 39 No. 6/2019)PubMedCrossRef Matiello M, Schaefer-Klein J, Sun D, Weinshenker BG (2013) Aquaporin-4 expression and tissue susceptibility to neuromyelitis optica. JAMA Neurol 70(09):1118–1125 (Seminars in Neurology Vol. 39 No. 6/2019)PubMedCrossRef
56.
go back to reference Saini H, Fernandez G, Kerr D, Levy M (2010) Differential expression of aquaporin-4 isoforms localizes with neuromyelitis optica disease activity. J Neuroimmunol 221(1–2):68–72PubMedCrossRef Saini H, Fernandez G, Kerr D, Levy M (2010) Differential expression of aquaporin-4 isoforms localizes with neuromyelitis optica disease activity. J Neuroimmunol 221(1–2):68–72PubMedCrossRef
57.
go back to reference Waters PJ, McKeon A, Leite MI, Rajasekharan S, Lennon VA, Villalobos A, Palace J, Mandrekar JN, Vincent A, Bar-Or A, Pittock SJ (2012) Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays. Neurology 78(9):665–671 (discussion 669)PubMedCrossRefPubMedCentral Waters PJ, McKeon A, Leite MI, Rajasekharan S, Lennon VA, Villalobos A, Palace J, Mandrekar JN, Vincent A, Bar-Or A, Pittock SJ (2012) Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays. Neurology 78(9):665–671 (discussion 669)PubMedCrossRefPubMedCentral
58.
go back to reference Kessler RA, Mealy MA, Jimenez-Arango JA, Quan C, Paul F, López R, Hopkins S, Levy M (2017) Anti-aquaporin-4 titer is not predictive of disease course in neuromyelitis optica spectrum disorder: a multicenter cohort study. Mult Scler Relat Disord 17:198–201PubMedCrossRef Kessler RA, Mealy MA, Jimenez-Arango JA, Quan C, Paul F, López R, Hopkins S, Levy M (2017) Anti-aquaporin-4 titer is not predictive of disease course in neuromyelitis optica spectrum disorder: a multicenter cohort study. Mult Scler Relat Disord 17:198–201PubMedCrossRef
59.
go back to reference Jitprapaikulsan J, Fryer JP, Majed M, Smith CY, Jenkins SM, Cabre P, Hinson SR, Weinshenker BG, Mandrekar J, Chen JJ, Lucchinetti CF, Jiao Y, Segan J, Schmeling JE, Mills J, Flanagan EP, McKeon A, Pittock SJ (2020) Clinical utility of AQP4-IgG titers and measures of complement-mediated cell killing in NMOSD. Neurol Neuroimmunol Neuroinflamm 7(4):e727PubMedCrossRefPubMedCentral Jitprapaikulsan J, Fryer JP, Majed M, Smith CY, Jenkins SM, Cabre P, Hinson SR, Weinshenker BG, Mandrekar J, Chen JJ, Lucchinetti CF, Jiao Y, Segan J, Schmeling JE, Mills J, Flanagan EP, McKeon A, Pittock SJ (2020) Clinical utility of AQP4-IgG titers and measures of complement-mediated cell killing in NMOSD. Neurol Neuroimmunol Neuroinflamm 7(4):e727PubMedCrossRefPubMedCentral
60.
go back to reference Jarius S, Ruprecht K, Wildemann B et al (2012) Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients. J Neuroinflamm 9:14CrossRef Jarius S, Ruprecht K, Wildemann B et al (2012) Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients. J Neuroinflamm 9:14CrossRef
61.
go back to reference Tajfirouz D, Padungkiatsagul T, Beres S, Moss HE, Pittock S, Flanagan E, Kunchok A, Shah S, Bhatti MT, Chen JJ (2022) Optic chiasm involvement in AQP-4 antibody-positive NMO and MOG antibody-associated disorder. Mult Scler 28(1):149–153PubMedCrossRef Tajfirouz D, Padungkiatsagul T, Beres S, Moss HE, Pittock S, Flanagan E, Kunchok A, Shah S, Bhatti MT, Chen JJ (2022) Optic chiasm involvement in AQP-4 antibody-positive NMO and MOG antibody-associated disorder. Mult Scler 28(1):149–153PubMedCrossRef
62.
go back to reference Kunchok A, Chen JJ, McKeon A, Mills JR, Flanagan EP, Pittock SJ (2020) Coexistence of myelin oligodendrocyte glycoprotein and aquaporin-4 antibodies in adult and pediatric patients. JAMA Neurol 77(2):257–259PubMedCrossRef Kunchok A, Chen JJ, McKeon A, Mills JR, Flanagan EP, Pittock SJ (2020) Coexistence of myelin oligodendrocyte glycoprotein and aquaporin-4 antibodies in adult and pediatric patients. JAMA Neurol 77(2):257–259PubMedCrossRef
63.
go back to reference Petzold A, Braithwaite T, van Oosten BW, Balk L, Martinez-Lapiscina EH, Wheeler R, Wiegerinck N, Waters C, Plant GT (2020) Case for a new corticosteroid treatment trial in optic neuritis: review of updated evidence. J Neurol Neurosurg Psychiatry 91(1):9–14PubMedCrossRef Petzold A, Braithwaite T, van Oosten BW, Balk L, Martinez-Lapiscina EH, Wheeler R, Wiegerinck N, Waters C, Plant GT (2020) Case for a new corticosteroid treatment trial in optic neuritis: review of updated evidence. J Neurol Neurosurg Psychiatry 91(1):9–14PubMedCrossRef
64.
go back to reference Siritho S, Nopsopon T, Pongpirul K (2021) Therapeutic plasma exchange vs conventional treatment with intravenous high dose steroid for neuromyelitis optica spectrum disorders (NMOSD): a systematic review and meta-analysis. J Neurol 268(12):4549–4562PubMedCrossRef Siritho S, Nopsopon T, Pongpirul K (2021) Therapeutic plasma exchange vs conventional treatment with intravenous high dose steroid for neuromyelitis optica spectrum disorders (NMOSD): a systematic review and meta-analysis. J Neurol 268(12):4549–4562PubMedCrossRef
65.
go back to reference Bonnan M, Valentino R, Debeugny S, Merle H, Fergé JL, Mehdaoui H, Cabre P (2018) Short delay to initiate plasma exchange is the strongest predictor of outcome in severe attacks of NMO spectrum disorders. J Neurol Neurosurg Psychiatry 89(4):346–351PubMedCrossRef Bonnan M, Valentino R, Debeugny S, Merle H, Fergé JL, Mehdaoui H, Cabre P (2018) Short delay to initiate plasma exchange is the strongest predictor of outcome in severe attacks of NMO spectrum disorders. J Neurol Neurosurg Psychiatry 89(4):346–351PubMedCrossRef
66.
go back to reference Trebst C, Jarius S, Berthele A, Paul F, Schippling S, Wildemann B, Borisow N, Kleiter I, Aktas O, Kümpfel T, Neuromyelitis Optica Study Group (NEMOS) (2014) Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol 261(1):1–16PubMedCrossRef Trebst C, Jarius S, Berthele A, Paul F, Schippling S, Wildemann B, Borisow N, Kleiter I, Aktas O, Kümpfel T, Neuromyelitis Optica Study Group (NEMOS) (2014) Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol 261(1):1–16PubMedCrossRef
67.
go back to reference Chen JJ, Flanagan EP, Pittock SJ, Stern NC, Tisavipat N, Bhatti MT, Chodnicki KD, Tajfirouz DA, Jamali S, Kunchok A, Eggenberger ER, Nome MAD, Sotirchos ES, Vasileiou ES, Henderson AD, Arnold AC, Bonelli L, Moss HE, Navarro SEV, Padungkiatsagul T, Stiebel-Kalish H, Lotan I, Wilf-Yarkoni A, Danesh-Meyer H, Ivanov S, Huda S, Forcadela M, Hodge D, Poullin P, Rode J, Papeix C, Saheb S, Boudot de la Motte M, Vignal C, Hacohen Y, Pique J, Maillart E, Deschamps R, Audoin B, Marignier R (2023) Visual outcomes following plasma exchange for optic neuritis: an international multicenter retrospective analysis of 395 optic neuritis attacks. Am J Ophthalmol 252:213–224PubMedCrossRef Chen JJ, Flanagan EP, Pittock SJ, Stern NC, Tisavipat N, Bhatti MT, Chodnicki KD, Tajfirouz DA, Jamali S, Kunchok A, Eggenberger ER, Nome MAD, Sotirchos ES, Vasileiou ES, Henderson AD, Arnold AC, Bonelli L, Moss HE, Navarro SEV, Padungkiatsagul T, Stiebel-Kalish H, Lotan I, Wilf-Yarkoni A, Danesh-Meyer H, Ivanov S, Huda S, Forcadela M, Hodge D, Poullin P, Rode J, Papeix C, Saheb S, Boudot de la Motte M, Vignal C, Hacohen Y, Pique J, Maillart E, Deschamps R, Audoin B, Marignier R (2023) Visual outcomes following plasma exchange for optic neuritis: an international multicenter retrospective analysis of 395 optic neuritis attacks. Am J Ophthalmol 252:213–224PubMedCrossRef
68.
go back to reference Levy M, Fujihara K, Palace J (2021) New therapies for neuromyelitis optica spectrum disorder. Lancet Neurol 20:60–67PubMedCrossRef Levy M, Fujihara K, Palace J (2021) New therapies for neuromyelitis optica spectrum disorder. Lancet Neurol 20:60–67PubMedCrossRef
69.
go back to reference Tahara M, Oeda T, Okada K, Kiriyama T, Ochi K, Maruyama H, Fukaura H, Nomura K, Shimizu Y, Mori M, Nakashima I, Misu T, Umemura A, Yamamoto K, Sawada H (2020) Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol 19(4):298–306PubMedCrossRef Tahara M, Oeda T, Okada K, Kiriyama T, Ochi K, Maruyama H, Fukaura H, Nomura K, Shimizu Y, Mori M, Nakashima I, Misu T, Umemura A, Yamamoto K, Sawada H (2020) Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol 19(4):298–306PubMedCrossRef
70.
go back to reference Pittock SJ, Berthele A, Fujihara K, Kim HJ, Levy M, Palace J, Nakashima I, Terzi M, Totolyan N, Viswanathan S, Wang KC, Pace A, Fujita KP, Armstrong R, Wingerchuk DM (2019) Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. N Engl J Med 381(7):614–625PubMedCrossRef Pittock SJ, Berthele A, Fujihara K, Kim HJ, Levy M, Palace J, Nakashima I, Terzi M, Totolyan N, Viswanathan S, Wang KC, Pace A, Fujita KP, Armstrong R, Wingerchuk DM (2019) Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. N Engl J Med 381(7):614–625PubMedCrossRef
71.
go back to reference Cree BAC, Bennett JL, Kim HJ, Weinshenker BG, Pittock SJ, Wingerchuk DM, Fujihara K, Paul F, Cutter GR, Marignier R, Green AJ, Aktas O, Hartung HP, Lublin FD, Drappa J, Barron G, Madani S, Ratchford JN, She D, Cimbora D, Katz E, N-Momentum Study Investigators (2019) Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial. Lancet 394(10206):1352–1363PubMedCrossRef Cree BAC, Bennett JL, Kim HJ, Weinshenker BG, Pittock SJ, Wingerchuk DM, Fujihara K, Paul F, Cutter GR, Marignier R, Green AJ, Aktas O, Hartung HP, Lublin FD, Drappa J, Barron G, Madani S, Ratchford JN, She D, Cimbora D, Katz E, N-Momentum Study Investigators (2019) Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial. Lancet 394(10206):1352–1363PubMedCrossRef
72.
go back to reference Traboulsee A, Greenberg BM, Bennett JL, Szczechowski L, Fox E, Shkrobot S, Yamamura T, Terada Y, Kawata Y, Wright P, Gianella-Borradori A, Garren H, Weinshenker BG (2020) Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial. Lancet Neurol 19(5):402–412PubMedCrossRefPubMedCentral Traboulsee A, Greenberg BM, Bennett JL, Szczechowski L, Fox E, Shkrobot S, Yamamura T, Terada Y, Kawata Y, Wright P, Gianella-Borradori A, Garren H, Weinshenker BG (2020) Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial. Lancet Neurol 19(5):402–412PubMedCrossRefPubMedCentral
73.
go back to reference Chen JJ, Pineles SL, Repka MX, Pittock SJ, Henderson RJ, Liu GT, Pediatric Eye Disease Investigator Group (PEDIG) (2021) MOG-IgG among participants in the pediatric optic neuritis prospective outcomes study. JAMA Ophthalmol 139(5):583–585PubMedCrossRefPubMedCentral Chen JJ, Pineles SL, Repka MX, Pittock SJ, Henderson RJ, Liu GT, Pediatric Eye Disease Investigator Group (PEDIG) (2021) MOG-IgG among participants in the pediatric optic neuritis prospective outcomes study. JAMA Ophthalmol 139(5):583–585PubMedCrossRefPubMedCentral
74.
go back to reference Song H, Zhou H, Yang M, Tan S, Wang J, Xu Q, Liu H, Wei S (2019) Clinical characteristics and prognosis of myelin oligodendrocyte glycoprotein antibody-seropositive paediatric optic neuritis in China. Br J Ophthalmol 103(6):831–836PubMedCrossRef Song H, Zhou H, Yang M, Tan S, Wang J, Xu Q, Liu H, Wei S (2019) Clinical characteristics and prognosis of myelin oligodendrocyte glycoprotein antibody-seropositive paediatric optic neuritis in China. Br J Ophthalmol 103(6):831–836PubMedCrossRef
75.
go back to reference Dubey D, Pittock SJ, Krecke KN, Morris PP, Sechi E, Zalewski NL, Weinshenker BG, Shosha E, Lucchinetti CF, Fryer JP, Lopez-Chiriboga AS, Chen JC, Jitprapaikulsan J, McKeon A, Gadoth A, Keegan BM, Tillema JM, Naddaf E, Patterson MC, Messacar K, Tyler KL, Flanagan EP (2019) Clinical, radiologic, and prognostic features of myelitis associated with myelin oligodendrocyte glycoprotein autoantibody. JAMA Neurol 76(3):301–309PubMedCrossRef Dubey D, Pittock SJ, Krecke KN, Morris PP, Sechi E, Zalewski NL, Weinshenker BG, Shosha E, Lucchinetti CF, Fryer JP, Lopez-Chiriboga AS, Chen JC, Jitprapaikulsan J, McKeon A, Gadoth A, Keegan BM, Tillema JM, Naddaf E, Patterson MC, Messacar K, Tyler KL, Flanagan EP (2019) Clinical, radiologic, and prognostic features of myelitis associated with myelin oligodendrocyte glycoprotein autoantibody. JAMA Neurol 76(3):301–309PubMedCrossRef
76.
go back to reference Asseyer S, Hamblin J, Messina S, Mariano R, Siebert N, Everett R, Küker W, Bellmann-Strobl J, Ruprecht K, Jarius S, Leite MI, Brandt UA, Paul F, Palace J (2020) Prodromal headache in MOG-antibody positive optic neuritis. Mult Scler Relat Disord 40:101965PubMedCrossRef Asseyer S, Hamblin J, Messina S, Mariano R, Siebert N, Everett R, Küker W, Bellmann-Strobl J, Ruprecht K, Jarius S, Leite MI, Brandt UA, Paul F, Palace J (2020) Prodromal headache in MOG-antibody positive optic neuritis. Mult Scler Relat Disord 40:101965PubMedCrossRef
77.
go back to reference Chen JJ, Sotirchos ES, Henderson AD, Vasileiou ES, Flanagan EP, Bhatti MT, Jamali S, Eggenberger ER, Dinome M, Frohman LP, Arnold AC, Bonelli L, Seleme N, Mejia-Vergara AJ, Moss HE, Padungkiatsagul T, Stiebel-Kalish H, Lotan I, Hellmann MA, Hodge D, Oertel FC, Paul F, Saidha S, Calabresi PA, Pittock SJ (2022) OCT retinal nerve fiber layer thickness differentiates acute optic neuritis from MOG antibody-associated disease and multiple sclerosis: RNFL thickening in acute optic neuritis from MOGAD vs MS. Mult Scler Relat Disord 58:103525PubMedCrossRefPubMedCentral Chen JJ, Sotirchos ES, Henderson AD, Vasileiou ES, Flanagan EP, Bhatti MT, Jamali S, Eggenberger ER, Dinome M, Frohman LP, Arnold AC, Bonelli L, Seleme N, Mejia-Vergara AJ, Moss HE, Padungkiatsagul T, Stiebel-Kalish H, Lotan I, Hellmann MA, Hodge D, Oertel FC, Paul F, Saidha S, Calabresi PA, Pittock SJ (2022) OCT retinal nerve fiber layer thickness differentiates acute optic neuritis from MOG antibody-associated disease and multiple sclerosis: RNFL thickening in acute optic neuritis from MOGAD vs MS. Mult Scler Relat Disord 58:103525PubMedCrossRefPubMedCentral
78.
go back to reference Stiebel-Kalish H, Lotan I, Brody J, Chodick G, Bialer O, Marignier R, Bach M, Hellmann MA (2017) Retinal nerve fiber layer may be better preserved in MOG-IgG versus AQP4-IgG optic neuritis: a cohort study. PLoS ONE 12(1):e0170847PubMedCrossRefPubMedCentral Stiebel-Kalish H, Lotan I, Brody J, Chodick G, Bialer O, Marignier R, Bach M, Hellmann MA (2017) Retinal nerve fiber layer may be better preserved in MOG-IgG versus AQP4-IgG optic neuritis: a cohort study. PLoS ONE 12(1):e0170847PubMedCrossRefPubMedCentral
79.
go back to reference Akaishi T, Sato DK, Nakashima I, Takeshita T, Takahashi T, Doi H, Kurosawa K, Kaneko K, Kuroda H, Nishiyama S, Misu T, Nakazawa T, Fujihara K, Aoki M (2016) MRI and retinal abnormalities in isolated optic neuritis with myelin oligodendrocyte glycoprotein and aquaporin-4 antibodies: a comparative study. J Neurol Neurosurg Psychiatry 87(4):446–448PubMedCrossRef Akaishi T, Sato DK, Nakashima I, Takeshita T, Takahashi T, Doi H, Kurosawa K, Kaneko K, Kuroda H, Nishiyama S, Misu T, Nakazawa T, Fujihara K, Aoki M (2016) MRI and retinal abnormalities in isolated optic neuritis with myelin oligodendrocyte glycoprotein and aquaporin-4 antibodies: a comparative study. J Neurol Neurosurg Psychiatry 87(4):446–448PubMedCrossRef
80.
go back to reference Gao C, Zhuo Z, Duan Y, Yao Y, Su L, Zhang X, Song T (2021) Structural and functional alterations in visual pathway after optic neuritis in MOG antibody disease: a comparative study with AQP4 seropositive NMOSD. Front Neurol 9(12):673472CrossRef Gao C, Zhuo Z, Duan Y, Yao Y, Su L, Zhang X, Song T (2021) Structural and functional alterations in visual pathway after optic neuritis in MOG antibody disease: a comparative study with AQP4 seropositive NMOSD. Front Neurol 9(12):673472CrossRef
81.
go back to reference Akaishi T, Himori N, Takeshita T, Misu T, Takahashi T, Takai Y, Nishiyama S, Kaneko K, Fujimori J, Ishii T, Aoki M, Fujihara K, Nakazawa T, Nakashima I (2022) Follow-up of retinal thickness and optic MRI after optic neuritis in anti-MOG antibody-associated disease and anti-AQP4 antibody-positive NMOSD. J Neurol Sci 15(437):120269CrossRef Akaishi T, Himori N, Takeshita T, Misu T, Takahashi T, Takai Y, Nishiyama S, Kaneko K, Fujimori J, Ishii T, Aoki M, Fujihara K, Nakazawa T, Nakashima I (2022) Follow-up of retinal thickness and optic MRI after optic neuritis in anti-MOG antibody-associated disease and anti-AQP4 antibody-positive NMOSD. J Neurol Sci 15(437):120269CrossRef
82.
go back to reference Sotirchos ES, Filippatou A, Fitzgerald KC, Salama S, Pardo S, Wang J, Ogbuokiri E, Cowley NJ, Pellegrini N, Murphy OC, Mealy MA, Prince JL, Levy M, Calabresi PA, Saidha S (2020) Aquaporin-4 IgG seropositivity is associated with worse visual outcomes after optic neuritis than MOG-IgG seropositivity and multiple sclerosis, independent of macular ganglion cell layer thinning. Mult Scler 26(11):1360–1371PubMedCrossRef Sotirchos ES, Filippatou A, Fitzgerald KC, Salama S, Pardo S, Wang J, Ogbuokiri E, Cowley NJ, Pellegrini N, Murphy OC, Mealy MA, Prince JL, Levy M, Calabresi PA, Saidha S (2020) Aquaporin-4 IgG seropositivity is associated with worse visual outcomes after optic neuritis than MOG-IgG seropositivity and multiple sclerosis, independent of macular ganglion cell layer thinning. Mult Scler 26(11):1360–1371PubMedCrossRef
83.
go back to reference Jang Y, Kim SM, Yun YI, Lee HJ, Kim SJ, Jung JH, Shin JH (2020) Comparison between optic neuritis associated with antibody against myelin oligodendrocyte glycoprotein and presumed idiopathic optic perineuritis. Neurol Sci 41(10):2755–2760PubMedCrossRef Jang Y, Kim SM, Yun YI, Lee HJ, Kim SJ, Jung JH, Shin JH (2020) Comparison between optic neuritis associated with antibody against myelin oligodendrocyte glycoprotein and presumed idiopathic optic perineuritis. Neurol Sci 41(10):2755–2760PubMedCrossRef
84.
go back to reference López-Chiriboga AS, Majed M, Fryer J, Dubey D, McKeon A, Flanagan EP, Jitprapaikulsan J, Kothapalli N, Tillema JM, Chen J, Weinshenker B, Wingerchuk D, Sagen J, Gadoth A, Lennon VA, Keegan BM, Lucchinetti C, Pittock SJ (2018) Association of MOG-IgG serostatus with relapse after acute disseminated encephalomyelitis and proposed diagnostic criteria for MOG-IgG-associated disorders. JAMA Neurol 75(11):1355–1363PubMedCrossRefPubMedCentral López-Chiriboga AS, Majed M, Fryer J, Dubey D, McKeon A, Flanagan EP, Jitprapaikulsan J, Kothapalli N, Tillema JM, Chen J, Weinshenker B, Wingerchuk D, Sagen J, Gadoth A, Lennon VA, Keegan BM, Lucchinetti C, Pittock SJ (2018) Association of MOG-IgG serostatus with relapse after acute disseminated encephalomyelitis and proposed diagnostic criteria for MOG-IgG-associated disorders. JAMA Neurol 75(11):1355–1363PubMedCrossRefPubMedCentral
85.
go back to reference Lopez-Chiriboga AS, Van Stavern G, Flanagan EP, Pittock SJ, Fryer J, Bhatti MT, Chen JJ (2019) Myelin oligodendrocyte glycoprotein antibody (MOG-IgG)-positive optic perineuritis. Neuroophthalmology 44(1):1–4PubMedCrossRefPubMedCentral Lopez-Chiriboga AS, Van Stavern G, Flanagan EP, Pittock SJ, Fryer J, Bhatti MT, Chen JJ (2019) Myelin oligodendrocyte glycoprotein antibody (MOG-IgG)-positive optic perineuritis. Neuroophthalmology 44(1):1–4PubMedCrossRefPubMedCentral
86.
go back to reference Vosoughi AR, Ling J, Tam KT, Blackwood J, Micieli JA (2021) Ophthalmic manifestations of myelin oligodendrocyte glycoprotein-IgG-associated disorder other than optic neuritis: a systematic review. Br J Ophthalmol 105:1591–1598PubMedCrossRef Vosoughi AR, Ling J, Tam KT, Blackwood J, Micieli JA (2021) Ophthalmic manifestations of myelin oligodendrocyte glycoprotein-IgG-associated disorder other than optic neuritis: a systematic review. Br J Ophthalmol 105:1591–1598PubMedCrossRef
87.
go back to reference O’Connor KC, McLaughlin KA, De Jager PL, Chitnis T, Bettelli E, Xu C, Robinson WH, Cherry SV, Bar-Or A, Banwell B, Fukaura H, Fukazawa T, Tenembaum S, Wong SJ, Tavakoli NP, Idrissova Z, Viglietta V, Rostasy K, Pohl D, Dale RC, Freedman M, Steinman L, Buckle GJ, Kuchroo VK, Hafler DA, Wucherpfennig KW (2007) Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein. Nat Med 13(2):211–217PubMedCrossRefPubMedCentral O’Connor KC, McLaughlin KA, De Jager PL, Chitnis T, Bettelli E, Xu C, Robinson WH, Cherry SV, Bar-Or A, Banwell B, Fukaura H, Fukazawa T, Tenembaum S, Wong SJ, Tavakoli NP, Idrissova Z, Viglietta V, Rostasy K, Pohl D, Dale RC, Freedman M, Steinman L, Buckle GJ, Kuchroo VK, Hafler DA, Wucherpfennig KW (2007) Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein. Nat Med 13(2):211–217PubMedCrossRefPubMedCentral
88.
go back to reference Jarius S, Paul F, Aktas O, Asgari N, Dale RC, de Seze J, Franciotta D, Fujihara K, Jacob A, Kim HJ, Kleiter I, Kümpfel T, Levy M, Palace J, Ruprecht K, Saiz A, Trebst C, Weinshenker BG, Wildemann B (2018) MOG encephalomyelitis: international recommendations on diagnosis and antibody testing. J Neuroinflamm 15(1):134CrossRef Jarius S, Paul F, Aktas O, Asgari N, Dale RC, de Seze J, Franciotta D, Fujihara K, Jacob A, Kim HJ, Kleiter I, Kümpfel T, Levy M, Palace J, Ruprecht K, Saiz A, Trebst C, Weinshenker BG, Wildemann B (2018) MOG encephalomyelitis: international recommendations on diagnosis and antibody testing. J Neuroinflamm 15(1):134CrossRef
89.
go back to reference Kitley J, Waters P, Woodhall M, Leite MI, Murchison A, George J, Küker W, Chandratre S, Vincent A, Palace J (2014) Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study. JAMA Neurol 71(3):276–283PubMedCrossRef Kitley J, Waters P, Woodhall M, Leite MI, Murchison A, George J, Küker W, Chandratre S, Vincent A, Palace J (2014) Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study. JAMA Neurol 71(3):276–283PubMedCrossRef
90.
go back to reference Ambrosius W, Michalak S, Kozubski W, Kalinowska A (2020) Myelin oligodendrocyte glycoprotein antibody-associated disease: current insights into the disease pathophysiology, diagnosis and management. Int J Mol Sci 22(1):100PubMedCrossRefPubMedCentral Ambrosius W, Michalak S, Kozubski W, Kalinowska A (2020) Myelin oligodendrocyte glycoprotein antibody-associated disease: current insights into the disease pathophysiology, diagnosis and management. Int J Mol Sci 22(1):100PubMedCrossRefPubMedCentral
91.
go back to reference Banwell B, Bennett JL, Marignier R, Kim HJ, Brilot F, Flanagan EP, Ramanathan S, Waters P, Tenembaum S, Graves JS, Chitnis T, Brandt AU, Hemingway C, Neuteboom R, Pandit L, Reindl M, Saiz A, Sato DK, Rostasy K, Paul F, Pittock SJ, Fujihara K, Palace J (2023) Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: international MOGAD Panel proposed criteria. Lancet Neurol 22(3):268–282PubMedCrossRef Banwell B, Bennett JL, Marignier R, Kim HJ, Brilot F, Flanagan EP, Ramanathan S, Waters P, Tenembaum S, Graves JS, Chitnis T, Brandt AU, Hemingway C, Neuteboom R, Pandit L, Reindl M, Saiz A, Sato DK, Rostasy K, Paul F, Pittock SJ, Fujihara K, Palace J (2023) Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: international MOGAD Panel proposed criteria. Lancet Neurol 22(3):268–282PubMedCrossRef
92.
go back to reference Banks SA, Morris PP, Chen JJ, Pittock SJ, Sechi E, Kunchok A, Tillema JM, Fryer JP, Weinshenker BG, Krecke KN, Lopez-Chiriboga AS, Nguyen A, Greenwood TM, Lucchinetti CF, Zalewski NL, Messina SA, Flanagan EP (2020) Brainstem and cerebellar involvement in MOG-IgG-associated disorder versus aquaporin-4-IgG and MS. J Neurol Neurosurg Psychiatry. https://doi.org/10.1136/jnnp-2020-325121CrossRefPubMed Banks SA, Morris PP, Chen JJ, Pittock SJ, Sechi E, Kunchok A, Tillema JM, Fryer JP, Weinshenker BG, Krecke KN, Lopez-Chiriboga AS, Nguyen A, Greenwood TM, Lucchinetti CF, Zalewski NL, Messina SA, Flanagan EP (2020) Brainstem and cerebellar involvement in MOG-IgG-associated disorder versus aquaporin-4-IgG and MS. J Neurol Neurosurg Psychiatry. https://​doi.​org/​10.​1136/​jnnp-2020-325121CrossRefPubMed
93.
go back to reference Reindl M, Waters P (2019) Myelin oligodendrocyte glycoprotein antibodies in neurological disease. Nat Rev Neurol 15(2):89–102PubMedCrossRef Reindl M, Waters P (2019) Myelin oligodendrocyte glycoprotein antibodies in neurological disease. Nat Rev Neurol 15(2):89–102PubMedCrossRef
94.
go back to reference Hennes EM, Baumann M, Schanda K, Anlar B, Bajer-Kornek B, Blaschek A, Brantner-Inthaler S, Diepold K, Eisenkölbl A, Gotwald T, Kuchukhidze G, Gruber-Sedlmayr U, Häusler M, Höftberger R, Karenfort M, Klein A, Koch J, Kraus V, Lechner C, Leiz S, Leypoldt F, Mader S, Marquard K, Poggenburg I, Pohl D, Pritsch M, Raucherzauner M, Schimmel M, Thiels C, Tibussek D, Vieker S, Zeches C, Berger T, Reindl M, Rostásy K, BIOMARKER Study Group (2017) Prognostic relevance of MOG antibodies in children with an acquired demyelinating syndrome. Neurology 89(9):900–908PubMedCrossRef Hennes EM, Baumann M, Schanda K, Anlar B, Bajer-Kornek B, Blaschek A, Brantner-Inthaler S, Diepold K, Eisenkölbl A, Gotwald T, Kuchukhidze G, Gruber-Sedlmayr U, Häusler M, Höftberger R, Karenfort M, Klein A, Koch J, Kraus V, Lechner C, Leiz S, Leypoldt F, Mader S, Marquard K, Poggenburg I, Pohl D, Pritsch M, Raucherzauner M, Schimmel M, Thiels C, Tibussek D, Vieker S, Zeches C, Berger T, Reindl M, Rostásy K, BIOMARKER Study Group (2017) Prognostic relevance of MOG antibodies in children with an acquired demyelinating syndrome. Neurology 89(9):900–908PubMedCrossRef
95.
go back to reference Fernandez-Carbonell C, Vargas-Lowy D, Musallam A, Healy B, McLaughlin K, Wucherpfennig KW, Chitnis T (2016) Clinical and MRI phenotype of children with MOG antibodies. Mult Scler 22(2):174–184PubMedCrossRef Fernandez-Carbonell C, Vargas-Lowy D, Musallam A, Healy B, McLaughlin K, Wucherpfennig KW, Chitnis T (2016) Clinical and MRI phenotype of children with MOG antibodies. Mult Scler 22(2):174–184PubMedCrossRef
96.
go back to reference Lechner C, Baumann M, Hennes EM, Schanda K, Marquard K, Karenfort M, Leiz S, Pohl D, Venkateswaran S, Pritsch M, Koch J, Schimmel M, Häusler M, Klein A, Blaschek A, Thiels C, Lücke T, Gruber-Sedlmayr U, Kornek B, Hahn A, Leypoldt F, Sandrieser T, Gallwitz H, Stoffels J, Korenke C, Reindl M, Rostásy K (2016) Antibodies to MOG and AQP4 in children with neuromyelitis optica and limited forms of the disease. J Neurol Neurosurg Psychiatry 87(8):897–905PubMedCrossRef Lechner C, Baumann M, Hennes EM, Schanda K, Marquard K, Karenfort M, Leiz S, Pohl D, Venkateswaran S, Pritsch M, Koch J, Schimmel M, Häusler M, Klein A, Blaschek A, Thiels C, Lücke T, Gruber-Sedlmayr U, Kornek B, Hahn A, Leypoldt F, Sandrieser T, Gallwitz H, Stoffels J, Korenke C, Reindl M, Rostásy K (2016) Antibodies to MOG and AQP4 in children with neuromyelitis optica and limited forms of the disease. J Neurol Neurosurg Psychiatry 87(8):897–905PubMedCrossRef
97.
go back to reference Baumann M, Sahin K, Lechner C, Hennes EM, Schanda K, Mader S, Karenfort M, Selch C, Häusler M, Eisenkölbl A, Salandin M, Gruber-Sedlmayr U, Blaschek A, Kraus V, Leiz S, Finsterwalder J, Gotwald T, Kuchukhidze G, Berger T, Reindl M, Rostásy K (2015) Clinical and neuroradiological differences of paediatric acute disseminating encephalomyelitis with and without antibodies to the myelin oligodendrocyte glycoprotein. J Neurol Neurosurg Psychiatry 86(3):265–272PubMedCrossRef Baumann M, Sahin K, Lechner C, Hennes EM, Schanda K, Mader S, Karenfort M, Selch C, Häusler M, Eisenkölbl A, Salandin M, Gruber-Sedlmayr U, Blaschek A, Kraus V, Leiz S, Finsterwalder J, Gotwald T, Kuchukhidze G, Berger T, Reindl M, Rostásy K (2015) Clinical and neuroradiological differences of paediatric acute disseminating encephalomyelitis with and without antibodies to the myelin oligodendrocyte glycoprotein. J Neurol Neurosurg Psychiatry 86(3):265–272PubMedCrossRef
98.
go back to reference Rostasy K, Mader S, Schanda K, Huppke P, Gärtner J, Kraus V, Karenfort M, Tibussek D, Blaschek A, Bajer-Kornek B, Leitz S, Schimmel M, Di Pauli F, Berger T, Reindl M (2012) Anti-myelin oligodendrocyte glycoprotein antibodies in pediatric patients with optic neuritis. Arch Neurol 69(6):752–756PubMedCrossRef Rostasy K, Mader S, Schanda K, Huppke P, Gärtner J, Kraus V, Karenfort M, Tibussek D, Blaschek A, Bajer-Kornek B, Leitz S, Schimmel M, Di Pauli F, Berger T, Reindl M (2012) Anti-myelin oligodendrocyte glycoprotein antibodies in pediatric patients with optic neuritis. Arch Neurol 69(6):752–756PubMedCrossRef
99.
go back to reference Baumann M, Grams A, Djurdjevic T, Wendel EM, Lechner C, Behring B, Blaschek A, Diepold K, Eisenkölbl A, Fluss J, Karenfort M, Koch J, Konuşkan B, Leiz S, Merkenschlager A, Pohl D, Schimmel M, Thiels C, Kornek B, Schanda K, Reindl M, Rostásy K (2018) MRI of the first event in pediatric acquired demyelinating syndromes with antibodies to myelin oligodendrocyte glycoprotein. J Neurol 265(4):845–855PubMedCrossRef Baumann M, Grams A, Djurdjevic T, Wendel EM, Lechner C, Behring B, Blaschek A, Diepold K, Eisenkölbl A, Fluss J, Karenfort M, Koch J, Konuşkan B, Leiz S, Merkenschlager A, Pohl D, Schimmel M, Thiels C, Kornek B, Schanda K, Reindl M, Rostásy K (2018) MRI of the first event in pediatric acquired demyelinating syndromes with antibodies to myelin oligodendrocyte glycoprotein. J Neurol 265(4):845–855PubMedCrossRef
100.
go back to reference Valencia-Sanchez C, Guo Y, Krecke KN, Chen JJ, Redenbaugh V, Montalvo M, Elsbernd PM, Tillema JM, Lopez-Chiriboga S, Budhram A, Sechi E, Kunchok A, Dubey D, Pittock SJ, Lucchinetti CF, Flanagan EP (2023) Cerebral cortical encephalitis in myelin oligodendrocyte glycoprotein antibody-associated disease. Ann Neurol 93(2):297–302PubMedCrossRef Valencia-Sanchez C, Guo Y, Krecke KN, Chen JJ, Redenbaugh V, Montalvo M, Elsbernd PM, Tillema JM, Lopez-Chiriboga S, Budhram A, Sechi E, Kunchok A, Dubey D, Pittock SJ, Lucchinetti CF, Flanagan EP (2023) Cerebral cortical encephalitis in myelin oligodendrocyte glycoprotein antibody-associated disease. Ann Neurol 93(2):297–302PubMedCrossRef
101.
go back to reference Carnero Contentti E, Lopez PA, Pettinicchi JP, Pappolla A, Miguez J, Patrucco L, Cristiano E, Vrech C, Tkachuk V, Liwacki S, Correale J, Marrodan M, Gaitán MI, Fiol M, Negrotto L, Ysrraelit MC, Burgos M, Leguizamon F, Tavolini D, Deri N, Balbuena ME, Mainella C, Luetic G, Blaya P, Hryb J, Menichini ML, Alvez Pinheiro A, Nofal P, Zanga G, Barboza A, Martos I, Lazaro L, Alonso R, Silva E, Bestoso S, Fracaro ME, Carrá A, Garcea O, Fernandez Liguori N, Alonso Serena M, Caride A, Rojas JI (2021) What percentage of AQP4-ab-negative NMOSD patients are MOG-ab positive? A study from the Argentinean multiple sclerosis registry (RelevarEM). Mult Scler Relat Disord 49:102742PubMedCrossRef Carnero Contentti E, Lopez PA, Pettinicchi JP, Pappolla A, Miguez J, Patrucco L, Cristiano E, Vrech C, Tkachuk V, Liwacki S, Correale J, Marrodan M, Gaitán MI, Fiol M, Negrotto L, Ysrraelit MC, Burgos M, Leguizamon F, Tavolini D, Deri N, Balbuena ME, Mainella C, Luetic G, Blaya P, Hryb J, Menichini ML, Alvez Pinheiro A, Nofal P, Zanga G, Barboza A, Martos I, Lazaro L, Alonso R, Silva E, Bestoso S, Fracaro ME, Carrá A, Garcea O, Fernandez Liguori N, Alonso Serena M, Caride A, Rojas JI (2021) What percentage of AQP4-ab-negative NMOSD patients are MOG-ab positive? A study from the Argentinean multiple sclerosis registry (RelevarEM). Mult Scler Relat Disord 49:102742PubMedCrossRef
102.
go back to reference Hamid SHM, Whittam D, Mutch K, Linaker S, Solomon T, Das K, Bhojak M, Jacob A (2017) What proportion of AQP4-IgG-negative NMO spectrum disorder patients are MOG-IgG positive? A cross sectional study of 132 patients. J Neurol 264(10):2088–2094PubMedCrossRefPubMedCentral Hamid SHM, Whittam D, Mutch K, Linaker S, Solomon T, Das K, Bhojak M, Jacob A (2017) What proportion of AQP4-IgG-negative NMO spectrum disorder patients are MOG-IgG positive? A cross sectional study of 132 patients. J Neurol 264(10):2088–2094PubMedCrossRefPubMedCentral
103.
go back to reference Sechi E, Buciuc M, Flanagan EP, Pittock SJ, Banks SA, Lopez-Chiriboga AS, Bhatti MT, Chen JJ (2021) Variability of cerebrospinal fluid findings by attack phenotype in myelin oligodendrocyte glycoprotein-IgG-associated disorder. Mult Scler Relat Disord 47:102638PubMedCrossRef Sechi E, Buciuc M, Flanagan EP, Pittock SJ, Banks SA, Lopez-Chiriboga AS, Bhatti MT, Chen JJ (2021) Variability of cerebrospinal fluid findings by attack phenotype in myelin oligodendrocyte glycoprotein-IgG-associated disorder. Mult Scler Relat Disord 47:102638PubMedCrossRef
104.
go back to reference Li X, Tian DC, Fan M, Xiu Y, Wang X, Li T, Jia D, Xu W, Song T, Shi FD, Zhang X (2020) Intravenous immunoglobulin for acute attacks in neuromyelitis optica spectrum disorders (NMOSD). Mult Scler Relat Disord 44:102325PubMedCrossRef Li X, Tian DC, Fan M, Xiu Y, Wang X, Li T, Jia D, Xu W, Song T, Shi FD, Zhang X (2020) Intravenous immunoglobulin for acute attacks in neuromyelitis optica spectrum disorders (NMOSD). Mult Scler Relat Disord 44:102325PubMedCrossRef
105.
go back to reference Hyun JW, Woodhall MR, Kim SH, Jeong IH, Kong B, Kim G, Kim Y, Park MS, Irani SR, Waters P, Kim HJ (2017) Longitudinal analysis of myelin oligodendrocyte glycoprotein antibodies in CNS inflammatory diseases. J Neurol Neurosurg Psychiatry 88(10):811–817PubMedCrossRef Hyun JW, Woodhall MR, Kim SH, Jeong IH, Kong B, Kim G, Kim Y, Park MS, Irani SR, Waters P, Kim HJ (2017) Longitudinal analysis of myelin oligodendrocyte glycoprotein antibodies in CNS inflammatory diseases. J Neurol Neurosurg Psychiatry 88(10):811–817PubMedCrossRef
106.
go back to reference Rostásy K, Mader S, Hennes EM, Schanda K, Gredler V, Guenther A, Blaschek A, Korenke C, Pritsch M, Pohl D, Maier O, Kuchukhidze G, Brunner-Krainz M, Berger T, Reindl M (2013) Persisting myelin oligodendrocyte glycoprotein antibodies in aquaporin-4 antibody negative pediatric neuromyelitis optica. Mult Scler 19(8):1052–1059PubMedCrossRef Rostásy K, Mader S, Hennes EM, Schanda K, Gredler V, Guenther A, Blaschek A, Korenke C, Pritsch M, Pohl D, Maier O, Kuchukhidze G, Brunner-Krainz M, Berger T, Reindl M (2013) Persisting myelin oligodendrocyte glycoprotein antibodies in aquaporin-4 antibody negative pediatric neuromyelitis optica. Mult Scler 19(8):1052–1059PubMedCrossRef
107.
go back to reference Waters P, Fadda G, Woodhall M, O’Mahony J, Brown RA, Castro DA, Longoni G, Irani SR, Sun B, Yeh EA, Marrie RA, Arnold DL, Banwell B, Bar-Or A, Canadian Pediatric Demyelinating Disease Network (2020) Serial anti-myelin oligodendrocyte glycoprotein antibody analyses and outcomes in children with demyelinating syndromes. JAMA Neurol 77(1):82–93PubMedCrossRef Waters P, Fadda G, Woodhall M, O’Mahony J, Brown RA, Castro DA, Longoni G, Irani SR, Sun B, Yeh EA, Marrie RA, Arnold DL, Banwell B, Bar-Or A, Canadian Pediatric Demyelinating Disease Network (2020) Serial anti-myelin oligodendrocyte glycoprotein antibody analyses and outcomes in children with demyelinating syndromes. JAMA Neurol 77(1):82–93PubMedCrossRef
108.
go back to reference Chen JJ, Flanagan EP, Bhatti MT, Tisavipat N, Jamali S, Kunchok A, Eggenberger ER, Nome MD, Sotirchos ES, Vasileiou ES, Henderson AD, Arnold AC, Bonelli L, Seleme N, Mejia-Vergara AJ, Moss HE, Padungkiatsagul T, Stiebel-Kalish H, Lotan I, Wilf-Yarkoni A, Hellmann MA, Vuppala A, Hodge D, Pittock SJ (2022) Details and outcomes of a large cohort of MOG-IgG associated optic neuritis. Mult Scler Relat Disord 68:104237PubMedCrossRef Chen JJ, Flanagan EP, Bhatti MT, Tisavipat N, Jamali S, Kunchok A, Eggenberger ER, Nome MD, Sotirchos ES, Vasileiou ES, Henderson AD, Arnold AC, Bonelli L, Seleme N, Mejia-Vergara AJ, Moss HE, Padungkiatsagul T, Stiebel-Kalish H, Lotan I, Wilf-Yarkoni A, Hellmann MA, Vuppala A, Hodge D, Pittock SJ (2022) Details and outcomes of a large cohort of MOG-IgG associated optic neuritis. Mult Scler Relat Disord 68:104237PubMedCrossRef
109.
go back to reference Whittam DH, Karthikeayan V, Gibbons E, Kneen R, Chandratre S, Ciccarelli O, Hacohen Y, de Seze J, Deiva K, Hintzen RQ, Wildemann B, Jarius S, Kleiter I, Rostasy K, Huppke P, Hemmer B, Paul F, Aktas O, Pröbstel AK, Arrambide G, Tintore M, Amato MP, Nosadini M, Mancardi MM, Capobianco M, Illes Z, Siva A, Altintas A, Akman-Demir G, Pandit L, Apiwattankul M, Hor JY, Viswanathan S, Qiu W, Kim HJ, Nakashima I, Fujihara K, Ramanathan S, Dale RC, Boggild M, Broadley S, Lana-Peixoto MA, Sato DK, Tenembaum S, Cabre P, Wingerchuk DM, Weinshenker BG, Greenberg B, Matiello M, Klawiter EC, Bennett JL, Wallach AI, Kister I, Banwell BL, Traboulsee A, Pohl D, Palace J, Leite MI, Levy M, Marignier R, Solomon T, Lim M, Huda S, Jacob A (2020) Treatment of MOG antibody associated disorders: results of an international survey. J Neurol 267(12):3565–3577PubMedCrossRefPubMedCentral Whittam DH, Karthikeayan V, Gibbons E, Kneen R, Chandratre S, Ciccarelli O, Hacohen Y, de Seze J, Deiva K, Hintzen RQ, Wildemann B, Jarius S, Kleiter I, Rostasy K, Huppke P, Hemmer B, Paul F, Aktas O, Pröbstel AK, Arrambide G, Tintore M, Amato MP, Nosadini M, Mancardi MM, Capobianco M, Illes Z, Siva A, Altintas A, Akman-Demir G, Pandit L, Apiwattankul M, Hor JY, Viswanathan S, Qiu W, Kim HJ, Nakashima I, Fujihara K, Ramanathan S, Dale RC, Boggild M, Broadley S, Lana-Peixoto MA, Sato DK, Tenembaum S, Cabre P, Wingerchuk DM, Weinshenker BG, Greenberg B, Matiello M, Klawiter EC, Bennett JL, Wallach AI, Kister I, Banwell BL, Traboulsee A, Pohl D, Palace J, Leite MI, Levy M, Marignier R, Solomon T, Lim M, Huda S, Jacob A (2020) Treatment of MOG antibody associated disorders: results of an international survey. J Neurol 267(12):3565–3577PubMedCrossRefPubMedCentral
110.
go back to reference Petzold A, Pittock S, Lennon V, Maggiore C, Weinshenker BG, Plant GT (2010) Neuromyelitis optica-IgG (aquaporin-4) autoantibodies in immune-mediated optic neuritis. J Neurol Neurosurg Psychiatry 81(1):109–111PubMedCrossRef Petzold A, Pittock S, Lennon V, Maggiore C, Weinshenker BG, Plant GT (2010) Neuromyelitis optica-IgG (aquaporin-4) autoantibodies in immune-mediated optic neuritis. J Neurol Neurosurg Psychiatry 81(1):109–111PubMedCrossRef
111.
go back to reference Lee HJ, Kim B, Waters P, Woodhall M, Irani S, Ahn S, Kim SJ, Kim SM (2018) Chronic relapsing inflammatory optic neuropathy (CRION): a manifestation of myelin oligodendrocyte glycoprotein antibodies. J Neuroinflamm 15(1):302CrossRef Lee HJ, Kim B, Waters P, Woodhall M, Irani S, Ahn S, Kim SJ, Kim SM (2018) Chronic relapsing inflammatory optic neuropathy (CRION): a manifestation of myelin oligodendrocyte glycoprotein antibodies. J Neuroinflamm 15(1):302CrossRef
112.
go back to reference Vosoughi AR, Micieli JA (2020) Resolution of myelin oligodendrocyte glycoprotein (MOG)-IgG optic neuritis without treatment. Mult Scler Relat Disord 46:102456PubMedCrossRef Vosoughi AR, Micieli JA (2020) Resolution of myelin oligodendrocyte glycoprotein (MOG)-IgG optic neuritis without treatment. Mult Scler Relat Disord 46:102456PubMedCrossRef
114.
go back to reference Chen JJ, Huda S, Hacohen Y, Levy M, Lotan I, Wilf-Yarkoni A, Stiebel-Kalish H, Hellmann MA, Sotirchos ES, Henderson AD, Pittock SJ, Bhatti MT, Eggenberger ER, Di Nome M, Kim HJ, Kim SH, Saiz A, Paul F, Dale RC, Ramanathan S, Palace J, Camera V, Leite MI, Lam BL, Bennett JL, Mariotto S, Hodge D, Audoin B, Maillart E, Deschamps R, Pique J, Flanagan EP, Marignier R (2022) Association of Maintenance intravenous immunoglobulin with prevention of relapse in adult myelin oligodendrocyte glycoprotein antibody-associated disease. JAMA Neurol 79(5):518–525PubMedCrossRefPubMedCentral Chen JJ, Huda S, Hacohen Y, Levy M, Lotan I, Wilf-Yarkoni A, Stiebel-Kalish H, Hellmann MA, Sotirchos ES, Henderson AD, Pittock SJ, Bhatti MT, Eggenberger ER, Di Nome M, Kim HJ, Kim SH, Saiz A, Paul F, Dale RC, Ramanathan S, Palace J, Camera V, Leite MI, Lam BL, Bennett JL, Mariotto S, Hodge D, Audoin B, Maillart E, Deschamps R, Pique J, Flanagan EP, Marignier R (2022) Association of Maintenance intravenous immunoglobulin with prevention of relapse in adult myelin oligodendrocyte glycoprotein antibody-associated disease. JAMA Neurol 79(5):518–525PubMedCrossRefPubMedCentral
115.
go back to reference Petzold A, Plant GT (2014) Chronic relapsing inflammatory optic neuropathy: a systematic review of 122 cases reported. J Neurol 261(1):17–26PubMedCrossRef Petzold A, Plant GT (2014) Chronic relapsing inflammatory optic neuropathy: a systematic review of 122 cases reported. J Neurol 261(1):17–26PubMedCrossRef
116.
go back to reference Kidd D, Burton B, Plant GT, Graham EM (2003) Chronic relapsing inflammatory optic neuropathy (CRION). Brain 126:276–284PubMedCrossRef Kidd D, Burton B, Plant GT, Graham EM (2003) Chronic relapsing inflammatory optic neuropathy (CRION). Brain 126:276–284PubMedCrossRef
117.
go back to reference Kurz D, Egan RA, Rosenbaum JT (2005) Treatment of corticosteroid dependent optic neuropathy with intravenous immunoglobulin. Am J Ophthalmol 140(6):1132–1133PubMedCrossRef Kurz D, Egan RA, Rosenbaum JT (2005) Treatment of corticosteroid dependent optic neuropathy with intravenous immunoglobulin. Am J Ophthalmol 140(6):1132–1133PubMedCrossRef
118.
go back to reference Palmi-Cortes I, Meca-Lallana V, Canneti B, Valenzuela-Rojas FJ, Vivancos J (2015) Recurrent optic neuritis: the importance of the differential diagnosis. Mult Scler, p 215, Abstract ECTRIMS Palmi-Cortes I, Meca-Lallana V, Canneti B, Valenzuela-Rojas FJ, Vivancos J (2015) Recurrent optic neuritis: the importance of the differential diagnosis. Mult Scler, p 215, Abstract ECTRIMS
119.
go back to reference Benoilid A, Tilikete C, Arndt C, Collengues N, Vignal-Clermont C, Vighetto A, De Seze J (2012) Relapsing inflammatory optic neuropathy: a multicenter study of 62 patients. Neurology 78:p.07.25151CrossRef Benoilid A, Tilikete C, Arndt C, Collengues N, Vignal-Clermont C, Vighetto A, De Seze J (2012) Relapsing inflammatory optic neuropathy: a multicenter study of 62 patients. Neurology 78:p.07.25151CrossRef
120.
go back to reference Fang B, McKeon A, Hinson SR, Kryzer TJ, Pittock SJ, Aksamit AJ, Lennon VA (2016) Autoimmune glial fibrillary acidic protein astrocytopathy: a novel meningoencephalomyelitis. JAMA Neurol 73(11):1297–1307PubMedCrossRef Fang B, McKeon A, Hinson SR, Kryzer TJ, Pittock SJ, Aksamit AJ, Lennon VA (2016) Autoimmune glial fibrillary acidic protein astrocytopathy: a novel meningoencephalomyelitis. JAMA Neurol 73(11):1297–1307PubMedCrossRef
121.
go back to reference Flanagan EP, Hinson SR, Lennon VA, Fang B, Aksamit AJ, Morris PP, Basal E, Honorat JA, Alfugham NB, Linnoila JJ, Weinshenker BG, Pittock SJ, McKeon A (2017) Glial fibrillary acidic protein immunoglobulin G as biomarker of autoimmune astrocytopathy: analysis of 102 patients. Ann Neurol 81:298–309PubMedCrossRef Flanagan EP, Hinson SR, Lennon VA, Fang B, Aksamit AJ, Morris PP, Basal E, Honorat JA, Alfugham NB, Linnoila JJ, Weinshenker BG, Pittock SJ, McKeon A (2017) Glial fibrillary acidic protein immunoglobulin G as biomarker of autoimmune astrocytopathy: analysis of 102 patients. Ann Neurol 81:298–309PubMedCrossRef
122.
go back to reference Yang X, Xu H, Ding M, Huang Q, Chen B, Yang H, Liu T, Long Y, Gao C (2018) Overlapping autoimmune syndromes in patients with glial fibrillary acidic protein antibodies. Front Neurol 25(9):251CrossRef Yang X, Xu H, Ding M, Huang Q, Chen B, Yang H, Liu T, Long Y, Gao C (2018) Overlapping autoimmune syndromes in patients with glial fibrillary acidic protein antibodies. Front Neurol 25(9):251CrossRef
123.
go back to reference Iorio R, Damato V, Evoli A, Gessi M, Gaudino S, Di Lazzaro V, Spagni G, Sluijs JA, Hol EM (2018) Clinical and immunological characteristics of the spectrum of GFAP autoimmunity: a case series of 22 patients. J Neurol Neurosurg Psychiatry 89(2):138–146PubMedCrossRef Iorio R, Damato V, Evoli A, Gessi M, Gaudino S, Di Lazzaro V, Spagni G, Sluijs JA, Hol EM (2018) Clinical and immunological characteristics of the spectrum of GFAP autoimmunity: a case series of 22 patients. J Neurol Neurosurg Psychiatry 89(2):138–146PubMedCrossRef
124.
go back to reference Chen JJ, Aksamit AJ, McKeon A, Pittock SJ, Weinshenker BG, Leavitt JA, Morris PP, Flanagan EP (2018) Optic disc edema in glial fibrillary acidic protein autoantibody-positive meningoencephalitis. J Neuroophthalmol 38(3):276–281PubMedCrossRef Chen JJ, Aksamit AJ, McKeon A, Pittock SJ, Weinshenker BG, Leavitt JA, Morris PP, Flanagan EP (2018) Optic disc edema in glial fibrillary acidic protein autoantibody-positive meningoencephalitis. J Neuroophthalmol 38(3):276–281PubMedCrossRef
125.
go back to reference De Lott LB, Bennett JL, Costello F (2022) The changing landscape of optic neuritis: a narrative review. J Neurol 269(1):111–124PubMedCrossRef De Lott LB, Bennett JL, Costello F (2022) The changing landscape of optic neuritis: a narrative review. J Neurol 269(1):111–124PubMedCrossRef
126.
go back to reference Bohm PE, Chen JJ, Bhatti TM, Eggenberger ER (2020) Neuro-ophthalmic features of autoimmune encephalitides. J Neuroophthalmol 40(3):385–397PubMedCrossRef Bohm PE, Chen JJ, Bhatti TM, Eggenberger ER (2020) Neuro-ophthalmic features of autoimmune encephalitides. J Neuroophthalmol 40(3):385–397PubMedCrossRef
127.
go back to reference White D, Mollan SP, Ramalingam S, Nagaraju S, Hayton T, Jacob S (2019) Enlarged and enhancing optic nerves in advanced glial fibrillary acidic protein meningoencephalomyelitis. J Neuroophthalmol 39(3):411–415PubMedCrossRef White D, Mollan SP, Ramalingam S, Nagaraju S, Hayton T, Jacob S (2019) Enlarged and enhancing optic nerves in advanced glial fibrillary acidic protein meningoencephalomyelitis. J Neuroophthalmol 39(3):411–415PubMedCrossRef
128.
go back to reference Sechi E, Morris PP, McKeon A, Pittock SJ, Hinson SR, Weinshenker BG, Sechi E, Morris PP, McKeon A, Pittock SJ, Hinson SR, Weinshenker BG, Aksamit AJ, Krecke KN, Kaufmann TJ, Jolliffe EA, Zalewski NL, Zekeridou A, Wingerchuk DM, Jitprapaikulsan J, Flanagan EP et al (2019) Glial fibrillary acidic protein IgG related myelitis: characterisation and comparison with aquaporin-4-IgG myelitis. J Neurol Neurosurg Psychiatry 90(4):488–490PubMedCrossRef Sechi E, Morris PP, McKeon A, Pittock SJ, Hinson SR, Weinshenker BG, Sechi E, Morris PP, McKeon A, Pittock SJ, Hinson SR, Weinshenker BG, Aksamit AJ, Krecke KN, Kaufmann TJ, Jolliffe EA, Zalewski NL, Zekeridou A, Wingerchuk DM, Jitprapaikulsan J, Flanagan EP et al (2019) Glial fibrillary acidic protein IgG related myelitis: characterisation and comparison with aquaporin-4-IgG myelitis. J Neurol Neurosurg Psychiatry 90(4):488–490PubMedCrossRef
129.
go back to reference Gravier-Dumonceau A, Ameli R, Rogemond V, Ruiz A, Joubert B, Muñiz-Castrillo S, Vogrig A, Picard G, Ambati A, Benaiteau M, Rulquin F, Ciron J, Deiva K, de Broucker T, Kremer L, Kerschen P, Sellal F, Bouldoires B, Genet R, Biberon J, Bigot A, Duval F, Issa N, Rusu EC, Goudot M, Dutray A, Devoize JL, Hopes L, Kaminsky AL, Philbert M, Chanson E, Leblanc A, Morvan E, Andriuta D, Diraison P, Mirebeau G, Derollez C, Bourg V, Bodard Q, Fort C, Grigorashvili-Coin I, Rieul G, Molinier-Tiganas D, Bonnan M, Tchoumi T, Honnorat J, Marignier R (2022) Glial fibrillary acidic protein autoimmunity: a French cohort study. Neurology 98(6):e653–e668PubMedCrossRefPubMedCentral Gravier-Dumonceau A, Ameli R, Rogemond V, Ruiz A, Joubert B, Muñiz-Castrillo S, Vogrig A, Picard G, Ambati A, Benaiteau M, Rulquin F, Ciron J, Deiva K, de Broucker T, Kremer L, Kerschen P, Sellal F, Bouldoires B, Genet R, Biberon J, Bigot A, Duval F, Issa N, Rusu EC, Goudot M, Dutray A, Devoize JL, Hopes L, Kaminsky AL, Philbert M, Chanson E, Leblanc A, Morvan E, Andriuta D, Diraison P, Mirebeau G, Derollez C, Bourg V, Bodard Q, Fort C, Grigorashvili-Coin I, Rieul G, Molinier-Tiganas D, Bonnan M, Tchoumi T, Honnorat J, Marignier R (2022) Glial fibrillary acidic protein autoimmunity: a French cohort study. Neurology 98(6):e653–e668PubMedCrossRefPubMedCentral
130.
go back to reference Long Y, Liang J, Xu H, Huang Q, Yang J, Gao C, Qiu W, Lin S, Chen X (2018) Autoimmune glial fibrillary acidic protein astrocytopathy in Chinese patients: a retrospective study. Eur J Neurol 25(3):477–483PubMedCrossRef Long Y, Liang J, Xu H, Huang Q, Yang J, Gao C, Qiu W, Lin S, Chen X (2018) Autoimmune glial fibrillary acidic protein astrocytopathy in Chinese patients: a retrospective study. Eur J Neurol 25(3):477–483PubMedCrossRef
131.
go back to reference Shu Y, Long Y, Chang Y, Li R, Sun X, Wang Y, Huang Y, Li J, Chen J, Yang Y, Lu Z, Hu X, Kermode AG, Qiu W (2018) Brain immunohistopathology in a patient with autoimmune glial fibrillary acidic protein astrocytopathy. NeuroImmunoModulation 25(1):1–6PubMedCrossRef Shu Y, Long Y, Chang Y, Li R, Sun X, Wang Y, Huang Y, Li J, Chen J, Yang Y, Lu Z, Hu X, Kermode AG, Qiu W (2018) Brain immunohistopathology in a patient with autoimmune glial fibrillary acidic protein astrocytopathy. NeuroImmunoModulation 25(1):1–6PubMedCrossRef
132.
go back to reference Dubey D, Hinson SR, Jolliffe EA, Zekeridou A, Flanagan EP, Pittock SJ, Basal E, Drubach DA, Lachance DH, Lennon VA, McKeon A (2018) Autoimmune GFAP astrocytopathy: prospective evaluation of 90 patients in 1 year. J Neuroimmunol 15(321):157–163CrossRef Dubey D, Hinson SR, Jolliffe EA, Zekeridou A, Flanagan EP, Pittock SJ, Basal E, Drubach DA, Lachance DH, Lennon VA, McKeon A (2018) Autoimmune GFAP astrocytopathy: prospective evaluation of 90 patients in 1 year. J Neuroimmunol 15(321):157–163CrossRef
133.
go back to reference Cross SA, Salomao DR, Parisi JE, Kryzer TJ, Bradley EA, Mines JA, Lam BL, Lennon VA (2003) Paraneoplastic autoimmune optic neuritis with retinitis defined by CRMP-5-IgG. Ann Neurol 54:38–50PubMedCrossRef Cross SA, Salomao DR, Parisi JE, Kryzer TJ, Bradley EA, Mines JA, Lam BL, Lennon VA (2003) Paraneoplastic autoimmune optic neuritis with retinitis defined by CRMP-5-IgG. Ann Neurol 54:38–50PubMedCrossRef
134.
go back to reference Dubey D, Lennon VA, Gadoth A, Pittock SJ, Flanagan EP, Schmeling JE, McKeon A, Klein CJ (2018) Autoimmune CRMP5 neuropathy phenotype and outcome defined from 105 cases. Neurology 90(2):e103–e110PubMedCrossRef Dubey D, Lennon VA, Gadoth A, Pittock SJ, Flanagan EP, Schmeling JE, McKeon A, Klein CJ (2018) Autoimmune CRMP5 neuropathy phenotype and outcome defined from 105 cases. Neurology 90(2):e103–e110PubMedCrossRef
135.
go back to reference Hotta A, Inatome R, Yuasa-Kawada J, Qin Q, Yamamura H, Yanagi S (2005) Critical role of collapsin response mediator protein-associated molecule CRAM for filopodia and growth cone development in neurons. Mol Biol Cell 16:32–39PubMedCrossRefPubMedCentral Hotta A, Inatome R, Yuasa-Kawada J, Qin Q, Yamamura H, Yanagi S (2005) Critical role of collapsin response mediator protein-associated molecule CRAM for filopodia and growth cone development in neurons. Mol Biol Cell 16:32–39PubMedCrossRefPubMedCentral
136.
go back to reference Cohen DA, Bhatti MT, Pulido JS, Lennon VA, Dubey D, Flanagan EP, Pittock SJ, Klein CJ, Chen JJ (2020) Collapsin response-mediator protein 5-associated retinitis, vitritis, and optic disc edema. Ophthalmology 127(2):221–229PubMedCrossRef Cohen DA, Bhatti MT, Pulido JS, Lennon VA, Dubey D, Flanagan EP, Pittock SJ, Klein CJ, Chen JJ (2020) Collapsin response-mediator protein 5-associated retinitis, vitritis, and optic disc edema. Ophthalmology 127(2):221–229PubMedCrossRef
137.
go back to reference Nakajima M, Uchibori A, Ogawa Y, Miyazaki T, Ichikawa Y, Kaneko K, Takahashi T, Nakashima I, Shiraishi H, Motomura M, Chiba A (2018) CV2/CRMP5-antibody-related paraneoplastic optic neuropathy associated with small-cell lung cancer. Intern Med 57:1645–1649PubMedCrossRefPubMedCentral Nakajima M, Uchibori A, Ogawa Y, Miyazaki T, Ichikawa Y, Kaneko K, Takahashi T, Nakashima I, Shiraishi H, Motomura M, Chiba A (2018) CV2/CRMP5-antibody-related paraneoplastic optic neuropathy associated with small-cell lung cancer. Intern Med 57:1645–1649PubMedCrossRefPubMedCentral
138.
go back to reference Martínez-Rubio C, Giralt L, Lacambra I, Artaraz J, Fonollosa A (2020) Paraneoplastic focal outer retinitis and optic neuropathy in a patient with small cell lung carcinoma and anti-CRMP5, anti-HU and anti-amphiphysin antibodies. Case Rep Ophthalmol 11(3):507–515PubMedCrossRefPubMedCentral Martínez-Rubio C, Giralt L, Lacambra I, Artaraz J, Fonollosa A (2020) Paraneoplastic focal outer retinitis and optic neuropathy in a patient with small cell lung carcinoma and anti-CRMP5, anti-HU and anti-amphiphysin antibodies. Case Rep Ophthalmol 11(3):507–515PubMedCrossRefPubMedCentral
139.
go back to reference Casswell EJ, Pringle E, Thuang C, Sanders MD, Graham EM (2016) clinical and histological features of small cell lung cancer paraneoplastic inflammatory uveitis. Ocul Immunol Inflamm 24(5):503–507PubMed Casswell EJ, Pringle E, Thuang C, Sanders MD, Graham EM (2016) clinical and histological features of small cell lung cancer paraneoplastic inflammatory uveitis. Ocul Immunol Inflamm 24(5):503–507PubMed
140.
go back to reference Saito M, Saito W, Kanda A, Ohguro H, Ishida S (2014) A case of paraneoplastic optic neuropathy and outer retinitis positive for autoantibodies against collapsin response mediator protein-5, recoverin, and α-enolase. BMC Ophthalmol 16(14):5CrossRef Saito M, Saito W, Kanda A, Ohguro H, Ishida S (2014) A case of paraneoplastic optic neuropathy and outer retinitis positive for autoantibodies against collapsin response mediator protein-5, recoverin, and α-enolase. BMC Ophthalmol 16(14):5CrossRef
141.
go back to reference de la Sayette V, Bertran F, Honnorat J, Schaeffer S, Iglesias S, Defer G (1998) Paraneoplastic cerebellar syndrome and optic neuritis with anti-CV2 antibodies: clinical response to excision of the primary tumor. Arch Neurol 55:405–408PubMedCrossRef de la Sayette V, Bertran F, Honnorat J, Schaeffer S, Iglesias S, Defer G (1998) Paraneoplastic cerebellar syndrome and optic neuritis with anti-CV2 antibodies: clinical response to excision of the primary tumor. Arch Neurol 55:405–408PubMedCrossRef
142.
go back to reference Pulido J, Cross SA, Lennon VA, Pulido J, Swanson D, Muench M, Lachance DH (2008) Bilateral autoimmune optic neuritis and vitreitis related to CRMP-5-IgG: intravitreal triamcinolone acetonide therapy of four eyes. Eye 22:1191–1193PubMedCrossRef Pulido J, Cross SA, Lennon VA, Pulido J, Swanson D, Muench M, Lachance DH (2008) Bilateral autoimmune optic neuritis and vitreitis related to CRMP-5-IgG: intravitreal triamcinolone acetonide therapy of four eyes. Eye 22:1191–1193PubMedCrossRef
143.
go back to reference Balcer LJ, Raynowska J, Nolan R, Galetta SL, Kapoor R, Benedict R, Phillips G, La Rocca N, Hudson L, Rudick R, Multiple Sclerosis Outcome Assessments Consortium (2017) Validity of low-contrast letter acuity as a visual performance outcome measure for multiple sclerosis. Mult Scler 23(5):734–747PubMedCrossRefPubMedCentral Balcer LJ, Raynowska J, Nolan R, Galetta SL, Kapoor R, Benedict R, Phillips G, La Rocca N, Hudson L, Rudick R, Multiple Sclerosis Outcome Assessments Consortium (2017) Validity of low-contrast letter acuity as a visual performance outcome measure for multiple sclerosis. Mult Scler 23(5):734–747PubMedCrossRefPubMedCentral
144.
go back to reference Raz N, Dotan S, Benoliel T, Chokron S, Ben-Hur T, Levin N (2011) Sustained motion perception deficit following optic neuritis: behavioral and cortical evidence. Neurology 76(24):2103–2111PubMedCrossRef Raz N, Dotan S, Benoliel T, Chokron S, Ben-Hur T, Levin N (2011) Sustained motion perception deficit following optic neuritis: behavioral and cortical evidence. Neurology 76(24):2103–2111PubMedCrossRef
145.
go back to reference Sabadia SB, Nolan RC, Galetta KM, Narayana KM, Wilson JA, Calabresi PA, Frohman EM, Galetta SL, Balcer LJ (2016) 20/40 or better visual acuity after optic neuritis: not as good as we once thought? J Neuroophthalmol 36(4):369–376PubMedCrossRef Sabadia SB, Nolan RC, Galetta KM, Narayana KM, Wilson JA, Calabresi PA, Frohman EM, Galetta SL, Balcer LJ (2016) 20/40 or better visual acuity after optic neuritis: not as good as we once thought? J Neuroophthalmol 36(4):369–376PubMedCrossRef
146.
go back to reference Costello F, Coupland S, Hodge W, Lorello GR, Koroluk J, Pan YI, Freedman MS, Zackon DH, Kardon RH (2006) Quantifying axonal loss after optic neuritis with optical coherence tomography. Ann Neurol 59(6):963–969PubMedCrossRef Costello F, Coupland S, Hodge W, Lorello GR, Koroluk J, Pan YI, Freedman MS, Zackon DH, Kardon RH (2006) Quantifying axonal loss after optic neuritis with optical coherence tomography. Ann Neurol 59(6):963–969PubMedCrossRef
147.
go back to reference Petzold A, Balcer LJ, Calabresi PA, Costello F, Frohman TC, Frohman EM, Martinez-Lapiscina EH, Green AJ, Kardon R, Outteryck O, Paul F, Schippling S, Vermersch P, Villoslada P, Balk LJ, ERN-EYE IMSVISUAL (2017) Retinal layer segmentation in multiple sclerosis: a systematic review and meta-analysis. Lancet Neurol 16(10):797–812PubMedCrossRef Petzold A, Balcer LJ, Calabresi PA, Costello F, Frohman TC, Frohman EM, Martinez-Lapiscina EH, Green AJ, Kardon R, Outteryck O, Paul F, Schippling S, Vermersch P, Villoslada P, Balk LJ, ERN-EYE IMSVISUAL (2017) Retinal layer segmentation in multiple sclerosis: a systematic review and meta-analysis. Lancet Neurol 16(10):797–812PubMedCrossRef
Metadata
Title
An update on optic neuritis
Authors
Jessica A. Kraker
John J. Chen
Publication date
05-08-2023
Publisher
Springer Berlin Heidelberg
Published in
Journal of Neurology / Issue 10/2023
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-023-11920-x

Other articles of this Issue 10/2023

Journal of Neurology 10/2023 Go to the issue